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Abstract 1
1.  Abstract 
Aim: The aim of this thesis was the analysis of copy number variations of the 
mitochondrial DNA (mtDNA) in several tissues and cell types with regard to different 
mitochondrial associated disorders. 
Background: The mtDNA copy number can be reduced due to mutations in the 
nuclear encoded DNA polymerase γ (POLG) or damages caused by deleterious 
reactive oxygen species (ROS), which are created by the respiratory chain. This 
leads to the insufficient expression of mitochondrial encoded subunits of complexes 
of the oxidative phosphorylation system (OXPHOS). Consequently an impairment of 
the biochemical activity and integrity of the cells occurs.  
Methods: The quantification of the mtDNA was performed by quantitative PCR 
(qPCR). Biochemical activities were determined by enzymatic assays such as direct 
measurement of the citrate synthase (CS) activity or comprehensive measurement of 
the respiratory activity. 
Results: Mutations in the nuclear inherited gene POLG result in mtDNA depletion in 
mitochondrial disorders including a mild phenotype of progressive external 
ophthalmoplegia (PEO) with epilepsy/ataxia. A mtDNA depletion was detected in 
different tissues and cell types of Alpers-Huttenlocher patients with pathogenic 
nuclear mutations. The mtDNA copy number was reduced in specific hippocampal 
regions of temporal lobe epilepsy (TLE) patients with Ammons’ horn sclerosis (AHS) 
accompanied by a decreased CS activity. An in vitro reduction of the mtDNA in 
fibroblasts results in an impaired respiratory activity. 
Conclusions: The mtDNA content is proportional to the mitochondria content and 
the energy demand of the respective tissue or cell type under normal conditions. A 
cell type- and tissue-specific depletion of the mtDNA can be present in several 
inherited and somatic mitochondrial disorders in vivo or can be generated by an in 
vitro system. The mtDNA depletion diminishes the biochemical activity and integrity 
of the cells and can contribute to the disease phenotype. 
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2. Introduction 
2.1 Roles of Mitochondria  
Eukaryotic cells contain a number of organelles with specialized functions like the 
mitochondria. Mitochondria are broadly known as double-membrane-bounded 
organelles, which perform a number of indispensable functions for the life of most 
eukaryotic cells (Henze and Martin, 2003). 
Their main function is the production of energy in the form of ATP via the citric acid 
cycle and the oxidative phosphorylation system (OXPHOS), but they are also 
involved in the biosynthesis of many metabolites like pyrimidines, amino acids or 
cellular iron sulphur cluster proteins (Attardi and Schatz, 1988; Bereiter-Hahn, 1990; 
Lill et al., 1999). A consequence of an OXPHOS dysfunction is a higher production of 
reactive oxygen species (ROS) (Camello-Almaraz et al., 2006). Mitochondria control 
the ability of the cell to generate and detoxificate ROS (Nicholls et al., 2003). 
Beside their role as ATP generators, mitochondria have also the ability to remove 
Ca2+ ions out of the cytosol and accumulate them in their matrix (Vasington and 
Murphy, 1962).  
The release of mitochondrial proapoptotic factors like cytochrome c into the 
cytoplasm can induce a signaling cascade, which plays a prominent role in apoptotic 
cell death (Hengartner, 2000). 
 
2.2 Energy generation via mitochondria  
The citric acid cycle, which takes place in the mitochondrial matrix, is a central 
metabolic pathway involved in the catabolic oxidation of substrates (figure 1; Krebs, 
1970).  
Acetyl-CoA, which is generated by the decomposition of nutrients such as glucose, 
transfers two carbon acetyl groups to oxaloacetate to generate citrate. The citrate is 
metabolized through a series of chemical transformations and releases two carboxyl 
groups as CO2. The energy-rich electrons generated by the cycle are transferred to 
NAD+/NADP+ and FAD+ to form NADH/NADPH and FADH2. The citric acid cycle is 
regulated by several substances like NADH, ATP and Ca2+ (Krebs, 1970). 
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Figure 1. Citric acid cycle (modified from Munnich, 2008). IMS – intermembrane space. 
 
The electrons generated via the citric acid cycle are afterwards transferred to the 
multisubunit enzyme complexes, also called oxidative phosphorylation system 
(OXPHOS), of the respiratory chain (Smeitink et al., 2001).  
The OXPHOS is embedded in the inner mitochondrial membrane (IMM). 
Functionally, it is composed of the five enzyme complexes NADH:ubiquinone 
oxidoreductase (complex I), succinate:ubiquinone oxidoreductase (complex II, 
succinate dehydrogenase, SDH), cytochrome c oxidoreductase (complex III, 
cytochrome bc1 complex), ubiquinol:ferricytochrome c:oxygen oxidoreductase 
(complex IV, COX) and F1F0-ATPase (complex V) as well as the two electron carriers 
coenzyme Q and cytochrome c (Chinnery and Schon, 2003; Hatefi, 1985; Saraste, 
1999; Schapira and Cock, 1999).  
 
The electrochemical gradient across the IMM transfers the energy of NADH/NADPH 
and FADH2 for the synthesis of ATP according to the chemiosmotic hypothesis 
(Mitchell, 1961). 
The electrons are transferred to oxygen to generate water at complex IV. The 
transport of electrons via the respiratory chain generates a proton gradient across the 
membrane (Smeitink et al., 2001), which is used to synthesize ATP by complex V 
(Saraste, 1999; Smeitink et al., 2001).  
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Superoxide anions are generated as side products of the OXPHOS mainly at 
complex I (Kudin et al., 2004; Murphy, 2009). A negligible amount is also produced at 
complex III (Kudin et al., 2004; Kudin et al., 2005; Murphy, 2009). The superoxide 
anions are released into the matrix by complex I and into the intermembrane space 
by complex III (figure 2; Kudin et al., 2004; Kudin et al., 2005).  
 
 
Figure 2. Generation of reactive oxygen species (ROS) at the oxidative phosphorylation system 
(OXPHOS) (modified from Kudin et al., 2005 and Smeitink et al., 2001). C – complex, IMS – 
intermembrane space, IMM - inner mitochondrial membrane, O2-• - superoxide anion. 
 
The energy equivalent ATP is not only required in typical metabolic household 
reactions of the cells, but also in tissue- and celltype-specific reactions. A notable 
example in this issue are neuronal cells, where the main ATP consuming reaction is 
the Na+/K+-ATPase, which stabilizes the Na+ electrochemical potential gradient 
across the neuronal plasma membrane (Nicholls et al., 2003).  
 
2.3 Mitochondrial DNA (mtDNA) and the interaction of mitochondria 
with the nucleus 
Mitochondria were originally independent prokaryotes, which were assimilated by 
other cells. This symbiosis (Schimper, 1883) led to the generation of eukaryotic cells 
(Margulis, 1981). Mitochondria transferred a part of their genome to the nucleus, but 
they still maintained genes, which are essential for their specific functions within the 
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cell (Margulis, 1981). They retained own metabolic functions and their own 
mitochondrial genome, though they also require proteins encoded by the nucleus and 
manufactured in the cytoplasm. In this context, the mitochondria evolved into 
semiautonomous organelles relying on the interaction with the nucleus (Thorsness 
and Weber, 1996).  
Most multiprotein enzyme complexes of the respiratory chain are partly encoded by 
both the nuclear and the mitochondrial DNA (Smeitink et al., 2001). The only enzyme 
complex exclusively encoded by nuclear DNA and therefore independent of the 
mtDNA background is complex II (Smeitink et al., 2001). 
It is assumed that different nuclear encoded isoforms could lead to tissue specific 
absences or defects in subunits thus preventing the correct synthesis of respiratory 
chain complexes (Johnson et al., 1983). This could result in a tissue specific or in a 
developmental dependent disease phenotype (Johnson et al., 1983). The conversion 
of a fetal to an adult form of the subunit can trigger the onset of such a disease 
(Johnson et al., 1983). 
 
Each mitochondrion is estimated to contain from two to ten copies of mtDNA 
(Graziewicz et al., 2006; Shuster et al., 1988; Wiesner et al., 1992). The mtDNA is 
packed into protein-DNA complexes called nucleoids (Chen and Butow, 2005; Wang 
and Bogenhagen, 2006). Each mitochondrion holds between one and more than ten 
nucleoids (Satoh and Kuroiwa, 1991).  
The nucleoids are suggested to occur in discrete membrane-spanning structures, the 
mitochondrial replisomes (Meeusen and Nunnari, 2003). These structures are 
proposed to provide a mechanism for linking mtDNA replication and transcription 
(Meeusen and Nunnari, 2003). Although the composition of the nucleoids is poorly 
understood, a high number of nuclear encoded proteins that control the mtDNA 
replication, the mtDNA transcription, the mitochondria fusion and the attachment of 
the nucleoids to the cytoskeleton have been detected (Chen and Butow, 2005; Wang 
and Bogenhagen, 2006). 
 
The mitochondrial genome contains 37 genes from which 13 are encoding proteins 
involved in the electron transport or oxidative phosphorylation of the respiratory chain 
(Anderson et al., 1981). The remaining genes encode for 22 mitochondrial tRNAs 
and 2 mitochondrial rRNAs (Anderson et al., 1981). Despite the fact, that 
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mitochondria possess their own DNA, this DNA only encodes for a small number of 
proteins. The majority of nearly 1000-1500 proteins located in the mitochondria are 
encoded by the nucleus (Calvo et al., 2006; Lopez et al., 2000). These nuclear 
encoded proteins strongly influence the localization, proliferation and metabolism of 
mitochondria. 
Nuclear encoded factors regulate the transcription and replication of the mtDNA. The 
essential protein for mtDNA replication is polymerase γ, the only nuclear encoded 
polymerase located within mitochondria (Graziewicz et al., 2006). 
  
2.4 Replication of mtDNA molecules 
Two types of mtDNA replication models exist, the asynchronous strand displacement 
model and a strand-coupled bidirectional replication model (figure 3). The two ways 
of mtDNA replication are both assumed to be present in eukaryotic cells. 
The unidirectional, asynchronous mtDNA replication model describes the initiation of 
the replication at two replication origins (Clayton, 1982). Both mtDNA strands 
dissociate during the initiation of the replication at the first origin. The synthesis 
process is performed unidirectionally at one strand, while the other single strand is 
displaced until the second replication origin is exposed. Then the replication is 
initiated in the opposite direction (figure 3; Clayton, 1982; Krishnan et al., 2008; 
Schmitt and Clayton, 1993; Shadel and Clayton, 1997).   
The bidirectional replication model describes an alternative strand-coupled 
mechanism. According to this model, the replication is initiated at one replication 
zone and proceeds symmetrically in both directions (figure 3; Bowmaker et al., 2003; 
Holt et al., 2000; Krishnan et al., 2008; Yao Yang et al., 2002).  
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Figure 3. mtDNA replication mechanisms (according to Graziewicz et al., 2006). A – bidirectional 
replication model, B – asynchronous replication model. 
 
A different balance between these replication mechanisms is assumed to influence 
the mtDNA copy number potentially in several physiological and developmental 
conditions (Holt et al., 2000). In cells increasing their mtDNA copy number, the 
bidirectional replication mechanism is predominantly observed. In contrast, in 
growing cells with lower mtDNA synthesis rate that mainly maintain a stable mtDNA 
copy number for the descendent daughter cells, the asynchronous mode of mtDNA 
replication occurs (Holt et al., 2000).  
 
2.5 Mitochondrial distribution 
The mitochondrial distribution is directly correlated with its cellular localization. An 
important aspect during the proliferation of cells is the allocation of mitochondria 
(Yaffe, 1999). It is assumed that a cellular machinery navigates the positioning and 
inheritance of mitochondria (Thorsness, 1992; Yaffe, 1999). Indicators for this 
process are the reticular morphology of mitochondria, their association with the 
cytoskeleton and moreover coordinated mitochondrial movements during cellular 
division and differentiation (Yaffe, 1999).  
 
Mitochondria are morphologically and functionally heterogeneous and form distinct 
populations with differing biochemical and respiratory properties within the cell 
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(Battersby and Moyes, 1998; Collins et al., 2002; Frazier et al., 2006; Gauthier and 
Padykula, 1966; Kayar et al., 1988; Lombardi et al., 2000). For instance, they are 
found to accumulate around the nucleus. This specific localization can potentially 
generate a hypoxic environment and protect the nuclear DNA from ionizing radiation 
(Bereiter-Hahn, 1990; Jones and Aw, 1988). Another example for the characteristic 
positioning of mitochondria refers to mitochondria in skeletal muscle fibers. A 
predominant accumulation takes place at the outer region of the sarcomere units of 
muscle fibers, the I-band level, whereas mitochondria occur in a low amount in the 
subsarcolemmal space (Kelley et al., 2002; Ogata and Yamasaki, 1997).  
This localization could be related to the demand for important molecules like oxygen  
diffusing over the outer mitochondrial membrane (OMM) (Jones and Aw, 1988). The 
morphological variations of mitochondria are intricately linked to many cellular 
processes, including development, cell cycle progression and apoptosis (Frazier et 
al., 2006). 
 
The mitochondria also form a largely interconnected, dynamic network (Frazier et al., 
2006; Rizzuto et al., 1998). Specialized cell types respond to their specific energy 
requirements with drastic changes of this mitochondrial network (Frazier et al., 2006; 
Minin et al., 2006). The localisation of mitochondria within this network can be altered 
by the transport of these organelles within the cell.  
A prominent example for mitochondrial transport within the cell is the transport of 
mitochondria in neuronal cells along the length of the axon to ensure the supply of 
ATP and the regulation of Ca2+ (Hollenbeck and Saxton, 2005; Minin et al., 2006). 
The observation that mitochondria feature heterogeneous populations within the cell, 
which communicate over a continuous network, has consequences for understanding 
the mechanisms that navigate the distribution of the mitochondrial DNA (mtDNA). 
 
2.6 Variations in the mtDNA  
The human mtDNA sequence with a length of 16,569 nucleotides was determined in 
1981 (Anderson et al., 1981). The maternally inherited mtDNA plays an essential role 
for the mitochondrial functionality and consequently for the survival of the cells.  
Deleterious changes in the mtDNA are known to contribute to several mitochondrial 
diseases. Prominent variations of the mtDNA are point mutations and deletions. 
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The correlation between the mtDNA and the disease phenotype exceeds the 
simplified picture of a cause-effect-relationship of sequence changes and the onset 
of a mitochondrial disorder. The genetics of mitochondria is unique from the 
Mendelian inheritance (Mendel, 1866) observed in the nucleus since cells have a 
variable number of mitochondria and each of these mitochondria contains several 
mtDNA molecules (Clay Montier et al., 2009).  
The mtDNA molecules in a cell can exist in a heteroplasmic state, which refers to a 
mixture of wildtype and mutant mtDNA molecules (Bender et al., 2006; Sciacco et al., 
1994; Taylor and Turnbull, 2005; Zsurka et al., 2005). The level of heteroplasmy can 
shift during transmission over generations (Chinnery et al., 2000) and also during 
tissue development (Chinnery et al., 1999; Nekhaeva et al., 2002).  
The accumulation of a fraction of mtDNA molecules, which is called heteroplasmic 
drift, can finally influence the physiology of the cell (Coller et al., 2001; Nekhaeva et 
al., 2002). This process has been termed clonal expansion (Coller et al., 2002; 
Nekhaeva et al., 2002). 
Different heteroplasmic levels of the cellular mtDNA content result in a mosaic 
pattern of a tissue with normal and deficient cells (Bender et al., 2006; Zsurka et al., 
2004). It is assumed that the heteroplasmic level of wildtype and mutant molecules 
has to reach a certain threshold before the mitochondrial function is impaired and a 
biochemical phenotype occurs (Rossignol et al., 2003; Sciacco et al., 1994). A 
prevalent example for the dependence of a disease phenotype on the heteroplasmic 
level are the syndromes neuropathy, ataxia and retinitis pigmentosa (NARP) and the 
maternally-inherited Leigh syndrome (MILS), which are both associated with the 
T8993G mtDNA mutation (Alexeyev et al., 2008; Mäkelä-Bengs et al., 1995). Patients 
with a heteroplasmic level of less than 60 % are generally asymptomatic. By contrast, 
patients with 60-90 % heteroplasmy are affected by NARP, whereas MILS is 
associated with a level of more than 90 % heteroplasmy (Alexeyev et al., 2008; 
Mäkelä-Bengs et al., 1995). 
 
Pathogenic single-nucleotide changes in the mitochondrial genome were firstly 
described in 1988 (Wallace et al., 1988) as a cause of the maternally inherited, 
neurological disorder Leber’s hereditary optic neuropathy (LHON). Since this time, 
several point mutations in the mtDNA have been identified and associated with a 
number of mitochondrial disorders like mitochondrial encephalomyopathy, lactic 
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acidosis and stroke-like episodes (MELAS) or myoclonic epilepsy and ragged red 
fibers (MERRF) (Chinnery and Schon, 2003; von Kleist-Retzow et al., 2003; Wallace, 
1992). The threshold value is often specific for the respective mtDNA point mutation 
and features a value of around 90 % (Rossignol et al., 2003). 
 
The presence of deletions of the mitochondrial genome in patients with mitochondrial 
myopathies was first reported in 1988 (Holt et al., 1988). Large-scale deletions of the 
mtDNA are found in specimen of about 40 % of adult patients affected by several 
mitochondrial myopathies, prevalently in chronic progressive external 
ophthalmopegia (PEO), Kearns-Sayre syndrome (KSS) and Pearson’s syndrome 
(Harding and Hammans, 1992; Holt et al., 1988; Holt et al., 1989a; Holt et al., 1989b; 
Porteous et al., 1998). The heteroplasmy level shows a range of 20-90 % of total 
mtDNA (Holt et al., 1988; Holt et al., 1989a). Defects of the respiratory chain occur at 
a threshold of 50-60 % heteroplasmy (Hayashi et al., 1991; Porteous et al., 1998).  
 
The deletions can be divided into two classes (Mita et al., 1990). Class I deletions are 
flanked by short nucleotide direct repeats (Holt et al., 1989b; Mita et al., 1990; Schon 
et al., 1989), whereas class II deletions possess no repeat elements (Mita et al., 
1990).  
The underlying mechanism causing mtDNA deletions is controversely discussed. The 
mtDNA deletions may arise from intramolecular recombination events mediated by 
enzymes that recognize short homologies (Holt et al., 1989b; Mita et al., 1990; Schon 
et al., 1989; Zsurka et al., 2005). On the other hand, they can potentially result from 
cleavage at topoisomerase sites (Blok et al., 1995; Nelson et al., 1989) or also 
generated as a result of slippage during replication (Holt et al., 1989b; Mita et al., 
1990;  Shoffner et al., 1989). 
 
The importance of the presence of a sufficient amount of wildtype molecules is 
reflected in a number of literature reports that point out the relationship between 
depletion of the mtDNA and the occurrence of a mitochondrial disease phenotype 
(Clay Montier et al., 2009; Durham et al., 2005).  
A severe reduction of the mtDNA copy number in tissues of clinically heterogeneous 
patients with mitochondrial encephalomyopathies was initially described by Moraes et 
al., 1991. The mtDNA depletion is a prominent hallmark of Alpers-Huttenlocher 
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syndrome (Naviaux et al., 1999) and accompanies several other mitochondrial 
disorders like mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) 
(Nishino et al., 1999; Papadimitriou et al., 1998). 
The degree of mtDNA depletion correlates with the severity of tissue involvement and 
the presence of biochemical defects (Treem and Sokol, 1998). The affected patients 
show an impaired respiratory chain activity due to a decrease of mtDNA encoded 
proteins (Moraes et al., 1991). 
 
2.7 Diseases associated with mitochondrial defects 
A wide range of diseases affecting various organs and cell types of the human body 
are associated with mitochondrial defects. This clinically, histologically, biochemically 
and genetically heterogeneous group of disorders (Chinnery and Schon, 2003) is 
correlated with deleterious variations of nuclear and mitochondrial genes (von Kleist-
Retzow et al., 2003).  
 
The mitochondrial disorders, which are based on a primary mtDNA defect, i.e. they 
result from specific changes of the mitochondrial DNA, include mitochondrial 
encephalopathy lactic acidosis with stroke-like episodes (MELAS), myoclonic 
epilepsy with ragged red fibers (MERRF), neuropathy, ataxia, and retinitis 
pigmentosa (NARP) or Kearns Sayre syndrome.  
 
In contrast, other mitochondrial diseases are related to a secondary mtDNA defect. 
These diseases result from defects in nuclear encoded genes, which have an impact 
on the mitochondrial genome. They include a range of disorders with Alpers-
Huttenlocher syndrome and progressive external ophthalmoplegia (PEO) as the most 
prominent examples. 
 
The clinical features and the neuropathology of the Alpers-Huttenlocher syndrome 
were initially described by Alpers (1931). The onset of the Alpers-Huttenlocher 
syndrome usually occurs during childhood (Harding et al., 1995).  
The syndrome is inherited in an autosomal recessive way (Huttenlocher et al., 1976; 
Sandbank and Lerman, 1972). It is a mtDNA depletion disorder, which is 
characterized by deficiency in mtDNA polymerase γ (POLG) resulting from specific 
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mutations in the nuclear gene POLG (Naviaux et al., 1999). Beside the high number 
of publications, where a mtDNA depletion was associated with Alpers-Huttenlocher 
syndrome, only few reports on mtDNA point mutations (Zsurka et al., 2008) or 
deletions (Ashley et al., 2008; Zsurka et al., 2008) exist. 
Hallmarks of this disease are a loss of neuronal cells, gliosis and demyelinization in 
the cerebral cortex and epileptic seizures in the brain (Alpers, 1931), paired with a 
decreased liver function (Huttenlocher et al., 1976). The impaired liver function is 
accompanied by hepatic lesions consisting of cirrhosis or of subacute hepatitis 
(Huttenlocher et al., 1976). Furthermore, elevated levels of glutamic oxaloacetate 
transaminase and lactic dehydrogenase are detected in liver serum (Huttenlocher et 
al., 1976). Biochemical characteristics are a deficiency of the partial mitochondrial 
encoded respiratory chain complexes I and IV in liver (Gauthier-Villars et al., 2001) 
and complexes I, III and IV in muscle (Naviaux et al., 1999). 
It has been reported that the metabolic defect underlying the Alpers-Huttenlocher 
syndrome predisposes to drug related hepatotoxicity, notably to sodium valproate, 
promoting hepatic failure (Gauthier-Villars et al., 2001; McFarland et al., 2008; 
Schwabe et al., 1997).  
 
Another mitochondrial disorder, which results from mutations in nuclear encoded 
proteins is progressive external ophthalmoplegia (PEO) (Graziewicz et al., 2006). 
PEO is characterized by ptosis, external ophthalmoplegia, cardiomyopathy and 
slowly progressive weakness of the skeletal muscle tissue (Bohlega et al., 1996; 
Copeland, 2008; Van Goethem et al., 2001; Zeviani et al., 1989). The autosomal 
dominant form of PEO (adPEO) is mainly associated with mutations in the nuclear 
genes POLG, Twinkle and adenine nucleotide translocator 1 (ANT1) (Spinazzola and 
Zeviani, 2005). A high number of mutations, which are correlated with PEO, have 
been detected in POLG (Chan and Copeland, 2009; Graziewicz et al., 2006). These 
mutations are also related to autosomal recessive PEO (arPEO) and sporadic PEO 
(Spinazzola and Zeviani, 2005).  Genetic hallmarks of PEO are multiple deletions and 
the accumulation of point mutations (Cardaioli et al., 2007; Spinazzola and Zeviani, 
2005; Zeviani et al., 1989). Biochemical characteristics are ragged red muscle fibers 
with abnormal mitochondria combined with a lowered respiratory activity (Copeland, 
2008; Graziewicz et al., 2006).  
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Mitochondrial defects are also involved in neurodegenerative disorders. The 
neurodegenerative diseases with mitochondrial impairment include morbus 
Parkinson (MP) (Jenner, 2003; Moore et al., 2005), Friedreich’s ataxia (FRDA) 
(Huang et al., 2006), Alzheimer’s disease (Blass and Gibson, 1991; Hirai et al., 2001; 
Maurer et al., 2000; Swerdlow et al., 1997), amyotrophic lateral sclerosis (ALS) 
(Bowling et al., 1993; Sasaki and Iwata, 1996; Wong et al., 1995) or temporal lobe 
epilepsy (TLE) with Ammon’s horn sclerosis (AHS) (Kunz, 2002; Kunz et al., 2000). 
The cause-effect-relationship between the disease phenotype and deleterious 
changes in mitochondria and their mtDNA remains to be elucidated (Kunz, 2002).  
  
The mesial temporal lobe epilepsy (TLE) is the best known and most intensively 
studied form of epilepsy (Sloviter, 2005). The hippocampal sclerosis or Ammon’s 
horn sclerosis (AHS) occurs as the prevalent pathological abnormality in brain 
specimen from patients with TLE (Liu et al., 1995; Sommer,1880).  
The hippocampus has the form of a curved tube, which can be divided into the 
subfield area dentata (AD) and the cornu ammonis (CA) sections one to four (figure 
4; Liu et al., 1995; Lopes da Silva and Arnolds, 1978). The AD contains a thick layer 
of small granule cells (Amaral and Lavenex, 2007; Liu et al., 1995; Lopes da Silva 
and Arnolds, 1978), whereas the CA regions are densely packed with pyramidal 
neurons (Amaral and Lavenex, 2007; Liu et al., 1995; Lopes da Silva and Arnolds, 
1978). The major pathway, where a signal flow is transmitted from the region AD to 
cornu ammonis 3 (CA3) and subsequently to cornu ammonis 1 (CA1), is named the 
trisynaptic circuit (Andersen et al., 1971) 
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Figure 4. Structure of the hippocampus (modified from Amaral and Lavenex, 2007; Chang and 
Lowenstein, 2003; Kudin et al., 2009; Lopes da Silva and Arnolds, 1978). A – cross-section scheme of 
the human brain; B – frontal section scheme of the human brain; C – Nissle stained slice of the 
hippocampus of a patient with parahippocampal lesion; D – graphical overview of the hippocampus 
structure. AD – area dentata; BS – brain stem; CA1 – cornu ammonis 1; CA3 – cornu ammonis 3; CB 
– cerebellum; FL – frontal lobe; H – hippocampus; OL – occipital lobe; PL – parietal lobe; TL – 
temporal lobe. 
 
In hippocampal sclerosis, a selective loss of pyramidal neurons in the regions CA1 
and CA3 occurs (Baron et al., 2007; Ben-Ari et al., 1980; Kunz et al., 2000; Liu et al., 
1994; Liu et al., 1995; Nadler, 1981). The accumulation of glia cells, which 
accompanies the neuronal cell loss, causes a shrinkage and hardening of the tissue 
named sclerosis (Chang and Lowenstein, 2003).  
The mechanisms causing the selective neuronal degeneration remain unclear (Baron 
et al., 2007). One of the factors could be an increased level of ROS, which has 
already been observed in various epilepsy models (Kovacs et al., 2001; Liang et al., 
2000). An increased ROS production is a hallmark of impaired mitochondria with an 
inhibited complex I activity (Han et al., 2001; Kudin et al., 2004). ROS can activate a 
vicious cycle, which results in mitochondrial degeneration and neuronal cell death 
(Kudin et al., 2004). 
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2.8 Polymerase γ (POLG) and POLG mutations 
The enzyme polymerase γ was primarily identified as an RNA-dependent DNA 
polymerase (Fridlender et al., 1972) and is among overall 16 mammalian 
polymerases the only polymerase detected in mammalian mitochondria (Bolden et 
al., 1977; Graziewicz et al., 2006). POLG is responsible for the replication and repair 
of the mtDNA (Graziewicz et al., 2006).  
The enzyme is a heterotrimer consisting of a catalytic and a dimeric accessory 
subunit (Carrodeguas et al., 2001).  
The gene POLG, which is localized on chromosome 15 with a length of 18.5 kbp and 
23 exons, encodes the catalytic subunit of POLG (figure 5; Ropp and Copeland, 
1996). This catalytic subunit is a 140 kDa enzyme with DNA-polymerase, 3’-5’- 
exonuclease and 5’-deoxyribose phosphate (dRP) lyase activities (Longley et al., 
1998a; Longley et al., 1998b; Ropp and Copeland, 1996). It contains a mitochondrial 
targeting sequence, an exonuclease domain with three Exo motifs (I-III) and a 
polymerase domain with three Pol motifs (A-C) (figure 5). These domains are 
connected by a linker region, which harbors four conserved blocks γ1-γ4 (figure 5; 
Chan and Copeland, 2009; Luoma et al., 2005; Ropp and Copeland, 1996). Another 
two conserved sequence elements (γ5 and γ6) are located in the polymerase domain 
(figure 5; Graziewicz et al., 2006). 
 
 
Figure 5. Catalytic subunit of POLG (modified from Chan and Copeland, 2009 and Graziewicz et al., 
2006). MTS – mitochondrial targeting sequence, I-III – Exo motifs, A-C – Pol motifs, γ1-γ6 – conserved 
sequence elements.   
  
The accessory subunit, encoded by the gene POLG2, is a 55 kDa protein, which is 
characterized as a processivity factor for DNA (Johnson et al., 2000; Lim et al., 
1999). Upon interaction with the catalytic subunit, p55 promotes tighter DNA binding 
to increase the polymerization rate (Johnson et al., 2000; Lim et al., 1999). 
 
The first pathogenic POLG and POLG2 mutations were identified in 2001 and 2006, 
respectively (Longley et al., 2006; Van Goethem et al., 2001). 
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A total of approximately 150 pathogenic mutations in POLG have been reported 
currently, which underlines the importance of POLG as a major locus for 
mitochondrial diseases (Chan and Copeland, 2009). These mutations can be 
localized in all regions of POLG (Chan and Copeland, 2009). 
Beside the broad number of known pathogenic mutations in POLG, plenty of neutral 
polymorphisms in this gene may influence moderately the variable genetic 
foundations and potentially even the susceptibility to mitochondrial defects within the 
human population. 
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3. Goals of this study 
Mitochondria are semiautonomous organelles with essential importance for the 
energy production of the cell. They contain their own mitochondrial DNA (mtDNA). 
Mitochondrial disorders can result from mtDNA mutations, which are intensively 
studied in a number of systemic mitochondrial diseases, as well as from rarely 
examined variations in the mtDNA content.   
 
Aim of this study was the analysis of molecularbiological variations in the mtDNA 
copy number in different human tissues and cell types.  
 
Firstly, it was planned to determine the total mtDNA copy number values of several 
tissues and cell types of healthy control patients.  
Subsequently, these values have to be compared with the mtDNA content of patients 
with the mitochondrial disorders Alpers-Huttenlocher syndrome and progressive 
external ophthalmoplegia (PEO) with epilepsy/ataxia.  
 
These disorders can be related to mutations in the nuclear gene POLG, which 
encodes for the catalytic subunit of polymerase γ (POLG). POLG, known as the only 
DNA polymerase present in mammalian mitochondria, is essential for the replication 
and repair of the mtDNA. The cause and consequences of the mtDNA depletion due 
to these disorders is of special interest.  
In this context, it was intended to examine the correlation between POLG and the 
mitochondrial phenotype. Relevant aspects of this correlation were the 
communication between the nucleus and the mitochondria as well as the effect of the 
inheritance of nuclear-encoded mutations on the onset of a mitochondrial disorder.  
 
Diseases with mitochondrial involvement like temporal lobe epilepsy (TLE) with 
Ammons’ horn sclerosis (AHS) can be expected to be associated with the occurrence 
of a mtDNA depletion. AHS is hallmarked by the selective loss of neuronal cells. The 
neuronal cell death is accompanied by the production of reactive oxygen species 
(ROS). An increased ROS production suggests mitochondrial degeneration. The 
cause and effect of mitochondrial changes during AHS still remains to be elucidated. 
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Therefore, it was interesting if mtDNA depletion specifically occurs in areas of 
selective loss of neuronal cells. 
 
In patients affected by a mild phenotype of PEO with epilepsy/ataxia, the 
accumulation of mtDNA deletions has been reported. The Alpers-Huttenlocher 
syndrome is regarded as mitochondrial depletion disorder. Only few reports about a 
low degree of mtDNA deletions in Alpers-Huttenlocher syndrome are available. 
It has to be evaluated if either the reduction of the mtDNA content or the amount of 
deleted molecules have a higher relevance for the onset of these disorders. 
 
The mtDNA depletion can lead to an impairment of the cellular metabolism. This 
includes that the dynamics of a decrease of the mtDNA content and the biochemical 
activity could be compared. It was of special interest to investigate if the reduction of 
the mtDNA and a possible decrease of the biochemical activity of the cells would be 
correlated in a linear relation or if a threshold value would exist.  
One possibility to determine the influence of the depletion on the respiratory skills is 
an in vitro assay. The advantages of this system are a short examination time and 
the opportunity to vary the favored parameters. 
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4. Materials and Methods 
4.1 Materials 
4.1.1 Synthetic oligodeoxynucleotides 
The following synthetic oligodeoxynucleotides for the mitochondrial genome 
(Anderson et al., 1981), the nuclear single copy gene Kir4.1 (GenBank accession no. 
U52155), and the nuclear low copy gene β-actin (GenBank accession no. 
NM_001101), purchased from the companies Thermo Fisher Scientific Inc. 
(Waltham, USA) and Eurofins MWG GmbH (Martinsried, Germany), were utilized in 
polymerase chain reactions: 
 
Table 1. Synthetic oligodeoxynucleotides for nuclear DNA as well as mitochondrial DNA (mtDNA). 
Locus Designation Region Direction Sequence 
KIR835F 835-853 forward 5’-GCGCAAAAGCCTCCTCATT-3’ 
KIR857TM 857-883 forward 
5’-FAM-
TGCCAGGTGACAGGAAAACTGCTTCAG-
TAMRA-3’ 
Kir4.1;  
nuclear 
KIR903R 903-885 reverse 5’-CCTTCCTTGGTTTGGTGGG-3’ 
BA341F 341-363 forward 5’-GGCACCACACCTTCTACAATGAG-3’ 
BA392TM 392-411 forward 
5’-FAM-TGCTGCTGACCGAGGCCCCC-
TAMRA-3’ 
β-Actin; 
nuclear 
BA444R 444-425 reverse 5’-GGTCATCTTCTCGCGGTTGG-3’ 
MT16520F 16520-16543 forward 5’-CATAAAGCCTAAATAGCCCACACG-3’ 
MT16557TM 16557-12 forward 
5’-FAM-AGACATCACGATGGATCACAGGTCT-
TAMRA-3’ 
mtDNA; 
mitochondrial 
MT35R 35-12 reverse 5’-CCGTGAGTGGTTAATAGGGTGATA-3’ 
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4.1.2 Enzymes, chemicals and solutions 
The following enzymes, chemicals and solutions were used: 
 
Table 2. Enzymes. 
Enzyme Company Registered Office 
acetyl coenzyme A Sigma-Aldrich St. Louis, USA 
catalase Serva Electrophoresis GmbH Heidelberg, Germany 
JumpStart Taq polymerase Sigma-Aldrich St. Louis, USA 
proteinase K QIAGEN N.V. Venlo, Netherlands 
restriction endonucleases and 
corresponding buffers 
New England Biolabs Ipswich, United Kingdom 
trypsin PAA Laboratories GmbH Pasching, Austria 
 
Table 3. Chemicals. 
Chemical Company Registered Office 
acetic acid Sigma-Aldrich St. Louis, USA 
ADP Sigma-Aldrich St. Louis, USA 
agarose Sigma-Aldrich St. Louis, USA 
boric acid Sigma-Aldrich St. Louis, USA 
bromophenol blue  Sigma-Aldrich St. Louis, USA 
cytochrome c Sigma-Aldrich St. Louis, USA 
DAB Sigma-Aldrich St. Louis, USA 
2’, 3’-dideoxycytidine Sigma-Aldrich St. Louis, USA 
digitonin Serva Electrophoresis GmbH Heidelberg, Germany 
disodium EDTA Sigma-Aldrich St. Louis, USA 
DMEM PAA Laboratories GmbH Pasching, Austria 
DMSO Merck Darmstadt, Germany 
dNTPs Sigma-Aldrich St. Louis, USA 
double distilled water Sigma-Aldrich St. Louis, USA 
DTNB Sigma-Aldrich St. Louis, USA 
EDTA Sigma-Aldrich St. Louis, USA 
ethidium bromide Sigma-Aldrich St. Louis, USA 
FBS Invitrogen Corporation Carlsbad, USA 
glutamic acid Sigma-Aldrich St. Louis, USA 
glycerol Sigma-Aldrich St. Louis, USA 
HCl Merck Darmstadt, Germany 
JumpStart buffer Sigma-Aldrich St. Louis, USA 
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KCl Sigma-Aldrich St. Louis, USA 
KHCO3 Sigma-Aldrich St. Louis, USA 
KH2PO4 Sigma-Aldrich St. Louis, USA 
K2HPO4 Sigma-Aldrich St. Louis, USA 
malate Sigma-Aldrich St. Louis, USA 
mannitol Sigma-Aldrich St. Louis, USA 
marker for DNA; 1 kb Ladder Sigma-Aldrich St. Louis, USA 
MgCl2 Sigma-Aldrich St. Louis, USA 
NaCl Sigma-Aldrich St. Louis, USA 
Na2HPO4 Sigma-Aldrich St. Louis, USA 
NBT Serva Electrophoresis GmbH Heidelberg, Germany 
NH4Cl Sigma-Aldrich St. Louis, USA 
oxaloacetic acid Sigma-Aldrich St. Louis, USA 
penicillin Invitrogen Corporation Carlsbad, USA 
pyruvic acid Sigma-Aldrich St. Louis, USA 
rotenone Sigma-Aldrich St. Louis, USA 
Rox reference dye Invitrogen Corporation Carlsbad, USA 
SDS Sigma-Aldrich St. Louis, USA 
streptomycin Invitrogen Corporation Carlsbad, USA 
succinate Sigma-Aldrich St. Louis, USA 
sucrose AppliChem GmbH Darmstadt, Germany 
triethanolamine Sigma-Aldrich St. Louis, USA 
tris Sigma-Aldrich St. Louis, USA 
Triton X-100 Sigma-Aldrich St. Louis, USA 
TTFB The uncoupler TTFB was a kind 
gift from Prof. Dr. B. Beechey. 
Institute for biological sciences, 
University of Wales, 
Aberystwyth, United Kingdom 
Tween 20 Sigma-Aldrich St. Louis, USA 
uridine Sigma-Aldrich St. Louis, USA 
xylene cyanol Merck Darmstadt, Germany 
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Table 4. Solutions. 
Solutions Ingredients 
brain media 
110 mM mannitol, 60 mM tris, 60 mM KCl, 10 mM KH2PO4, 0.5 mM 
NaEDTA, pH 7.4 
cell freezing media 90 % [v/v] FBS, 10 % [v/v] DMSO 
fibroblast media 
DMEM (4.5 g/l glucose, GlutaMAX, 1 mM sodium pyruvate), 10 % [v/v] 
FBS, uridine (0.005 g/l), penicillin (100,000 U/l), streptomycin (0.1 g/l) 
laser dissection buffer 1x JumpStart buffer, 0.1x TE buffer,  0.005 % [v/v] Tween 20 
loading dye 
1x TBE buffer, 30 % [v/v] glycerol, 0.04 % [w/v] bromphenol blue, 0.04 % 
[w/v] xylene cyanole 
lysis buffer A 155 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA, pH 7.4 
lysis buffer B 0.5 % [w/v] SDS, 10 mM EDTA, pH 7.4 
PBS 
137 mM NaCl, 2.68 mM KCl, 7.48 mM Na2HPO4·12 H2O, 1.37 mM 
K2HPO4, pH 7.4 
SE buffer 75 mM NaCl, 25 mM EDTA, pH 8 
staining solution for 
cytochrome c oxidase (COX)  
219 mM sucrose, 50 mM Na2HPO4 ·12 H2O, 2.52 mM DAB·4 HCl·2 H2O, 
161.5 µM cytochrome c, 16.67 µM catalase (≙ 2,600 U), pH 7.4 
staining solution for succinate 
dehydrogenase (SDH)  
50 mM succinate, 12.5 mM tris-HCl, 2.5 mM MgCl2·6 H2O, 61.15 µM 
NBT, pH 7.4 
TAE buffer (10x) 400 mM tris-acetate, 10 mM EDTA, pH 8.0 
TBE buffer (10x) 890 mM tris-borate, 20 mM EDTA, pH 8.3 
TE buffer 10 mM tris-HCl, 1 mM EDTA, pH 7.4 
trypsin solution 2.5 mg/ml trypsin in 1x PBS, pH 7-7.5 
 
4.1.3 Kits 
The following kits were utilized: 
 
Table 5. Kits. 
Kit Company Registered Office 
QIAamp DNA Mini Kit QIAGEN N.V. Venlo, Netherlands 
QIAquick Gel Extraction Kit QIAGEN N.V. Venlo, Netherlands 
QIAquick PCR Purification Kit QIAGEN N.V. Venlo, Netherlands 
Total Protein Kit, Micro Lowry, Peterson’s Modification Sigma-Aldrich St. Louis, USA 
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4.1.4 Equipment 
The following electronic equipment was used in the experiments: 
 
Table 6. Measurement equipment. 
Electronic equipment Model Company Registered Office 
oxygraph 
OROBOROS Oxygraph-
2k 
OROBOS® 
INSTRUMENTS GmbH 
Innsbruck, Austria 
quantitative real time 
PCR (qPCR) 
thermocycler 
iCycler Thermal Cycler Bio-Rad Hercules, USA 
spectrophotometer Cary 50 scan Varian, Inc. Palo Alto, USA 
 
Table 7. Other equipment. 
Electronic equipment Model Company Registered Office 
analytical balance TE214S sartorius Elk Grove, USA 
camera 
3 CCD Color Video 
Camera, Model DXC-
9100P 
Sony Corporation Minato, Japan 
epi-fluorescence 
microscope 
Eclipse E800 Nikon Tokyo, Japan 
gel electrophoresis 
chamber 
Sub-cell GT System Bio-Rad Hercules, USA 
haemocytometer 
BLAUBRAND, 
Neubauer, IVD 
BRAND GMBH + CO KG Wertheim, Germany 
homogenizer ultraturrax homogenizer IKA Staufen, Germany 
PCR thermocycler 
GeneAmp PCR system 
9700 
Applied Biosystems Carlsbad, USA 
PCR thermocycler MJ Research PTC-100 GMI, Inc. Ramsey, USA 
phase contrast 
microscope 
Axiovert 40 C Carl Zeiss AG Jena, Germany 
pH meter InoLab pH 720 WTW Weilheim, Germany 
power supply PowerPac 300 Bio-Rad Hercules, USA 
sonicator ultrasonic processor GENEC Montreal, Canada 
UV illuminator Geldoc XR Bio-Rad Hercules, USA 
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For the analysis of the experiments the following software was utilized: 
 
Table 8. Measurement software. 
Application area Software Company Registered Office 
qPCR 
MyiQ Single-Color Real-
Time PCR Detection 
System 
Bio-Rad Hercules, USA 
respirometry OROBOROS DatLab 
OROBOS® 
INSTRUMENTS GmbH 
Innsbruck, Austria 
spectrophotometry CaryWinUV Varian, Inc. Palo Alto, USA 
 
Table 9. Other software. 
Application area Software Company Registered Office 
formula derivation Maple Waterloo Maple Inc. Waterloo, Canada 
laser dissectioning PalmWin 2.2.2A Carl Zeiss AG Jena, Germany 
microscope image 
capturing 
Lucia 32 G / Magic Nikon Tokyo, Japan 
plotting and data 
analysis 
SigmaPlot 2001 Systat Software Inc. San José, USA 
raster graphics editor Adobe Photoshop Adobe Systems San José, USA 
statistical analysis GraphPad Prism 5 GraphPad Software, Inc. San Diego, USA 
vector graphics editor CorelDraw Corel Corporation Ottawa, Canada 
 
4.2 Patients and human material 
4.2.1 Patient ascertainment 
The study was performed according to the guidelines of the University Ethical 
Commission. All patients or their respective guardians gave consent to the scientific 
use of their anonymized data. The clinical data of the patients were provided by the 
Departments of Epileptology and Neurology, University Bonn. 
 
4.2.2 Human samples 
The control DNA samples were obtained from routine skeletal muscle biopsies 
without signs of mitochondrial disease, from brain surgery samples of patients with 
Material and Methods                                                                                                25 
 
 
 
temporal lobe epilepsy, from post mortem liver as well as from blood samples, buccal 
mucosa and skin fibroblasts of patients not suspect of mitochondrial disorder.  
 
4.2.3 Cell lines 
HeLa cells were applied as a control tumor cell line. The HeLa TG wildtype cell line 
and the according HeLa EB8 ρ0 cell line (Hayashi et al., 1991; Hayashi et al., 1994) 
were kind gifts from Prof. Dr. Rudolf Wiesner from the Institute of Vegetative 
Physiology, University Cologne. 
 
4.3 Cell culture 
4.3.1 Thawing cells 
The fibroblasts were stored in liquid nitrogen at –195 °C. For cultivation, they were 
quickly thawed to 37 °C and transferred to a tissue culture flask with desired size and 
required amount of fibroblast media (table 4). The cells were maintained in a cell 
incubator at 37 °C and 5 % CO2.  
 
4.3.2 Passaging cells 
For passaging of the cells, the fibroblast media of the flask was aspirated and 
discarded. The cells were washed with 1x PBS and then detached by incubation in 
2.5 mg/ml trypsin solution (table 2; table 4) at 37 °C. Trypsin cleaves the cell 
adhesion proteins. The trypsinised state of the cells was controlled under the 
microscope. After resuspending the cells in the required amount of fibroblast media, 
they were transferred to new tissue culture flasks.  
 
4.3.3 Cell counting  
Firstly, the fibroblasts were removed from the bottom of the culture dish with trypsin 
(paragraph 4.3.2) and resuspended in fibroblast media. 20 µl of this solution were 
transferred to a Neubauer haemocytometer and inspected using a microscope. For 
determination of the cell count, results from eight type A squares of the Neubauer 
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haemocytometer with a volume of 1 mm3 each were averaged. On the basis of these 
data the total cell amount was calculated.   
 
4.3.4 Depletion treatment 
For depletion of mitochondrial DNA (mtDNA), cells were cultivated in fibroblast  
media containing 1mM pyruvate, 0.005 g/l uridine and either 0.13 µM ethidium 
bromide (EtBr) or 20 µM 2’, 3’-dideoxycytidine (ddC). 
 
4.3.5 Freezing cells 
Trypsinised cells were resuspended in the desired amount of fibroblast media and 
centrifuged at 1,000 g for 5 min. After discarding the supernatant, the cells were 
resuspended in the required amount of cold cell freezing media (table 4). The cells 
were aliquoted in cryo reaction tubes and cooled down for 1 h at – 20 °C, then for 24 
h at – 80 °C and finally in liquid nitrogen. By this slow cooling, the cells were 
protected from mechanical destruction by ice crystal formation.  
 
4.4 DNA analysis 
4.4.1 DNA isolation from blood by salting out 
Lysis of red blood cells was carried out by adding 30 ml cooled lysis buffer A (table 4) 
to 10 ml EDTA-anticoagulated blood. After incubation for 30 min on ice, the sample 
was centrifuged at 1,000 g and 4 °C for 10 min. The supernatant was removed 
afterwards. The sample was carefully swayed in 10 ml of lysis buffer A and 
centrifuged again as before. Subsequently, the supernatant was removed, the pellet 
was rinsed with 10 ml of 0.15 M KCl and centrifuged at 1,000 g and 4 °C for 10 min. 
The pellet was mixed in 5 ml SE buffer (table 4) containing 0.9 % SDS [w/v] and 
0.045 mg/ml proteinase K. After incubation at 55 °C for 1 h, the pellet was shaked 
vigorously in 1.7 ml 5 M NaCl and centifuged for 15 min and 5,000 g at room 
temperature. The supernatant was transferred to a new reaction tube. The DNA was 
precipitated as a thread by adding 2 volumes of pure ethanol and carefully swaying. 
The DNA thread was transferred to a new reaction tube, dried, dissolved in the 
desired amount of TE buffer (table 4) and stored at 4 °C. 
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4.4.2 DNA isolation from fibroblasts by salting out 
Lysis of fibroblasts was performed by addition of lysis buffer B (table 4) containing 
0.2 mg/ml proteinase K and incubation with shaking at 37 °C overnight. The DNA 
was precipitated by adding 0.3 volumes of 5 M NaCl and mixing vigorously for 15 s. 
The sample was centifuged at 5,000 g for 15 min at room temperature. The 
supernatant and 2 volumes of pure ethanol were inverted for 1 min.  The DNA was 
centrifuged at 5,000 g for 10 min. The pellet was washed with 1 ml 70 % ethanol [v/v] 
and dried. The DNA was solved in the desired amount of TE buffer and stored at 4 
°C. 
 
4.4.3 DNA isolation with the QIAamp DNA Mini Kit 
The DNA isolation was performed as specified in the manual of the QIAamp DNA 
Mini Kit (QIAGEN N.V., Venlo, Netherlands). 
 
4.4.4 DNA isolation from liver slices 
Cytochrome c oxidase (COX)-positive and COX-negative regions (paragraph 4.5.4) 
of 10 µm thick liver tissue slices were cut out on a phase contrast microscope with 
laser dissection. A region of approximately 50 cells was cut out. Cells were lysed in 
laser dissection buffer containing 1.67 mg/ml proteinase K.  
 
4.4.5 Photometric quantitation of the nucleic acid concentration  
The determination of the nucleic acid concentration occured by measurement of the 
optical density with a spectral photometer. Double-stranded DNA showed an 
absorption maximum at the wavelength λ = 260 nm, whereas proteins possessed an 
absorption maximum at the wavelength λ = 280 nm. 1 OD260nm unit corresponded to 
50 µg/ml for double-stranded DNA and accordingly 40 µg/ml for single-stranded DNA 
and RNA. The ratio OD260nm /OD280nm provided an estimate of the degree of purity of 
the nucleic acid. The quality of the DNA was considered suitable if it featured a ratio 
between 1.8 and 2.0.  
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4.4.6 DNA mutation analysis 
DNA mutation analysis using restriction fragment length polymorphism (RFLP) 
analysis of PCR fragments were performed in the Department of Epileptology, 
University Bonn. The application of RFLP analysis involved cutting the DNA using 
restriction endonucleases to distinguish between wildtype and mutated molecules. 
The size of the resulting DNA fragments was analysed on polyacrylamide gels and, 
when required, further examined by sequencing. 
 
4.4.7 Quantitative PCR (qPCR) 
With the PCR method, an exponential amplification of DNA fragments of variable size 
is possible due to a heat resistant Taq polymerase (Mullis and Faloona, 1987). As a 
result of heat denaturation, single-stranded templates are formed, allowing an 
annealing of primers at a lower temperature. In this way, complementary copies can 
be elongated along the templates.  
qPCR is a modification of this method allowing the monitoring of the DNA 
amplification in real time. The most prominent techniques for the time being are using 
either SYBR Green I or specific probes. SYBR Green I intercalates between the 
strands of the DNA and therefore stains DNA in an unspecific way. Specific probes 
such as TaqMan probes contain, based on the effect of fluorescence resonance 
energy transfer (FRET; Förster, 1946), a fluorophore and a quencher molecule. The 
TaqMan probe binds to a specific sequence during the annealing phase and is 
degenerated by the Taq polymerase as the template is elongated. The fluorescence 
signal of the fluorophore is no longer quenched after spatial separation of both 
molecules. This results in the fluorescence signal detectable in real time of the PCR. 
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Table 10. qPCR reaction mix. 
Component Volume [µl] Final concentration 
double distilled water 6.36  
MgCl2 (25 mM) 2.5 2.5 mM 
10x JumpStart buffer 
containing 1.5 % Triton X-100 
2.5 1x 
DMSO 0.38 1.5 % 
dNTPs (25 mM each) 0.2 200 µM each 
50x Rox reference dye 0.13 0.26x 
JumpStart Taq polymerase 
(2.5 U/µl) 0.13 0.31 U 
primer forward (12.5 pmol/µl) 0.3 150 nM 
primer reverse (12.5 pmol/µl) 0.3 150 nM 
TaqMan probe (12.5 pmol/µl) 0.2 100 nM 
DNA sample 12  
total volume 25  
 
Table 11. qPCR amplification protocol. * Cycles recorded by the camera of the qPCR thermocycler 
(table 6 and 8). 
Step Temperature [°C] Time [s] Cycles 
denaturation 95 180 1 
denaturation 95 15 
annealing/elongation 60 60 45*  
 
 
denaturation 95 60 1 
infinite hold 16 ∞ 1 
 
Several analysis methods for determination of the cycle number (CT-value) are 
existing. They are generally divided into the fit points method (Freeman et al., 1999; 
Pfaffl, 2001; Wittwer and Kusukawa, 2004; Wittwer et al., 1997), the second 
derivative maximum method (Tichopad et al., 2002; Zhao and Fernald, 2005) and the 
sigmoidal curve fit method (Liu and Saint, 2002; Rutledge, 2004).  
 
Applying the fit points method, a threshold line is adjusted parallel to the x-axis. The 
x-axis is defining the strength of the fluorescence signal, the y-axis is related to the 
cycle number. The CT-values are thus acquired in the region of the fluorescence 
curve measured by qPCR, where all reactions are in the exponential phase. 
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However, choosing the threshold line depends on subjective judgement of the user 
(Zhao and Fernald, 2005). 
With the second derivative maximum method and the sigmoidal curve fit method, the 
second derivative of the curve is calculated. The CT-value is determined by taking 
either the maximum of the second derivative using the second derivative maximum 
method or the zero value that is the inflection point using the sigmoidal curve fit 
method. The maximum of the second derivative curve corresponds to the beginning 
and the inflection point to the center of the linear phase of the fluorescence curve. It 
was shown by mathematical modeling of individual amplification reactions that a four-
parametric sigmoidal curve-fitting shows remarkable accuracy and reliability 
(Rutledge, 2004).   
 
For this reason, the CT-value was calculated using the sigmoidal curve fit method on 
the basis of the inflection point of the regression equation (SigmaPlot 2001; table 9). 
The data collected by qPCR were fitted with a sigmoidal regression curve, namely 
Chapman curve, with four parameters provided by the software with the equation: 
  
y y0 a 1 e
bx c
 
 
The four parameters y0, a, b and c determined the shape of the curve and the degree 
of the exponential function. 
 
For determination of the inflection point, this equation was differentiated using the 
mathematical software maple. 
The first derivative was: 
 
f ' x a 1 e
bx c
c be bx
1 e bx
 
 
The second derivative was:  
 
f ' ' x a 1 e
bx c
c
2 b2 e bx 2
1 e bx 2
a 1 e bx c c b2 e bx
1 e bx
a 1 e bx c c b2 e bx 2
1 e bx 2
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The inflection point can be calculated setting the second derivative to zero: 
 
f ' ' 0 ln c
b
 
 
The CT-value equales to the x coordinate of the inflection point of the fluorescence 
curve. For each value, three dilutions were performed each in triplicate experiments. 
Furthermore, the arithmetic mean and the standard deviation of each triplicate were 
calculated. 
 
The mtDNA copy number was deduced on the basis of the proportion of a single 
copy nuclear gene to the mtDNA content. 
The cycle number difference (D) was calculated from the mean cycle number values 
of the reference gene (cR) and the gene of interest (cI): 
 
D= cR− cI
 
 
From this, the absolute copy number (CN) of the gene of interest was derived: 
 
CN = 2D
 
 
The relation between a diploid single copy nuclear gene and a mitochondrial 
sequence is hence calculated as following: 
 
CN 2D 2
 
 
To determine the efficiency of the reaction, a serial dilution of the measured CT-
values of DNA samples was plotted against their initial concentration in a 
semilogarithmic scale. Every dilution series contained three dilutions each in 
triplicates. 
Statistically viewed, the total amount of DNA is duplicated in each reaction cycle 
according to an efficiency of 100 %.  In this case, the negative correlation between 
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slope and intercept would have a value of –1.  The slope s and the efficiency E were 
related to each other as following:  
 
E 1
s
100
 
 
4.5 Enzymatic assays 
4.5.1 Protein content determination 
The determination of the protein content of cells was performed by using the Total 
Protein Kit, Micro Lowry, Peterson’s Modification from Sigma-Aldrich (St. Louis, USA) 
according to Bensadoun and Weinstein (1976), Lowry et al. (1951), and Peterson 
(1977). 
 
4.5.2 Citrate synthase (CS) assay 
Tissue specimen or cells were pre-treated to release CS from the mitochondrial 
matrix. Frozen muscle or brain samples were homogenized in 0.1 M phosphate 
buffer (pH 7.4) with a homogenizer three times for 15 s at 24,000 rpm. The 
homogenate was centrifuged for 10 min, 4 °C at 20,000 g. For CS measurement, the 
supernatant was used. The homogenized tissue supernatant or cells diluted in 1x 
PBS were sonificated three times for 15 s with a sonicator.  
 
The CS measurement was carried out in a modified way according to Bergmeyer 
(1970). CS was used as a marker of the mitochondrial matrix. CS catalyzed the 
following reaction: 
 
Figure 6. Reaction of acetyl coenzyme A (Acetyl-CoA) and oxaloacetic acid to citric acid and CoA-SH. 
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The thiolgroup of the product CoA-SH can be detected using 5, 5’-dithiobis-(2-
nitrobenzoic acid) (DTNB): 
 
 
Figure 7. Reaction of 5, 5’-dithiobis-(2-nitrobenzoic acid) (DTNB) and CoA-SH to 5-Thio-2-
nitrobenzoic acid (TNB) and CoA-S-S-TNB. 
 
The yellow coloured TNB was detected spectrophotometrically by measuring the 
absorption maximum at the wavelength λ = 412 nm. 
 
Table 12. CS reaction mix. 
Component Volume [ml] Final concentration in the reaction 
double distilled water 0.81  
DTNB (1mM, in 1 M tris-HCl, pH 8.1) 0.1 0.1 mM in 100 mM tris-HCl 
oxalacetic acid (50 mM, in 500 mM 
triethanolamine, 5 mM NaEDTA) 0.05 
2.5 mM in 25 mM triethanolamine, 0.25 mM 
NaEDTA 
acetyl-CoA (12 mM) 0.03 0.36 mM 
homogenate 0.01  
total volume 1  
 
Firstly, the background signal was measured, then the colorimetric reaction was 
started by adding 0.01 ml of the homogenate. 
 
The activity of the photometric measured CS was calculated with the following 
formula: 
CS activity
E412
min
V dil
ε
mM L V enz
 
 
∆E412 refers to the absorption difference measured at the wavelength λ = 412 nm. 
εmM specifies the particular extinction coefficient. The extinction coefficient of TNB at 
λ = 412 nm has a value of 13.6 mM-1⋅cm-1. L and V are determining the length and 
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volume of the cuvette. Venz exhibits the volume of the sample. The formula contains 
additionally the dilution factor dil when indicated. 
 
4.5.3 Determination of the oxygen consumption 
Examinations of the oxygen consumption were performed with an oxygraph (table 6; 
table 8) at 30 °C. To determine the respiratory activity of cells dependent on NADH 
dehydrogenase (complex I), 2 ml brain media (table 4) containing additionally 10 mM 
pyruvate, 5 mM malate and 3.33 mM MgCl2 were filled into the oxygraph chamber. 
After closing the oxygraph chamber, the background changes in oxygen 
concentration, referring to the error of the electrode, were measured. The basic 
respiration of cells was detected after adding 100 µl cells diluted in brain media. The 
cells were permeabilized with 6.67 µM digitonin. By adding 2 mM ADP, the activity of 
mitochondria was stimulated. Apart from the addition of the substrates pyruvate and 
malate, 10 mM glutamate, another substrate of complex I, was injected to exclude an 
influence of pyruvate dehydrogenase on the reaction. To enhance respiration of cells 
further, an amount of 200 nM uncoupler TTFB was added three times to the 
oxygraph chamber. 
 
The succinate dehydrogenase (complex II) dependent respiration was measured in 
the following way: 2 ml brain media containing additionally 3.33 mM MgCl2 and 1 µm 
rotenone were filled into the oxygraph chamber. Rotenone inhibits complex I by 
blocking its ubiquinone binding site. Firstly, the background was measured. 
Afterwards, 100 µl cell solution and then 10 mM succinate, the substrate for complex 
II, were injected. The cells were permeabilized by adding 6.67 µM digitonin. By 
injection of 2 mM ADP the activity of mitochondria was stimulated. The respiration of 
cells was further enhanced by adding three times 200 nM TTFB. 
 
4.5.4 Immunohistochemistry 
Cryostat sections of liver slices (6 µm) were double-stained for cytochrome c oxidase 
(COX) and succinate dehydrogenase (SDH) as described by Dubowitz (1985) and 
Seligman et al. (1968). COX (complex IV) is encoded both by nuclear and 
mitochondrial genes. From the presence of the COX staining signal, the mtDNA 
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integrity can be deduced. SDH, the complex II of the respiratory chain, is encoded 
only by nuclear genes. SDH therefore indicates the occurrence of mitochondria 
independently from their mtDNA background. For a COX-SDH double-staining, tissue 
slices were incubated in COX staining solution (table 4) for 60 min and subsequently 
in SDH staining solution (table 4) for 90 min. The slices were then fixed in 4 % 
formalin for 5 min. All staining and fixation steps were followed by washing the 
respective slice three times in 1x PBS. The staining of slices was performed in the 
Department of Neurology, University Bonn.  
 
4.6 Statistical analyses 
For statistical analyses, the software programs Microsoft Office Excel and Graph Pad 
Prism 5 were utilized (table 9).  
The difference of two empirical determined mean values belonging to two normally 
distributed sample populations was analysed using the student’s t-test. The zero 
hypothesis indicates that the difference between those mean values is generated 
accidentally and that the mean values are identical. The probability of the occurence 
of a positive zero hypothesis was examined with the student’s t-test. Level of 
significance was scaled to at least p < 0.05. Generally, a two-sided t-test for 
independent sample populations was applied.  
A number of greater than two normally distributed sample populations was 
statistically analyzed using an one-way analysis of variance (ANOVA). In this regard 
the hypothesis, if the variance between the examined groups is bigger than the 
variance within these groups, was tested. The result of the ANOVA was further 
specified using a Dunnett test (Dunnett, 1955; Dunnett, 1964) comparing the 
variance of each sample population to the variance of the control population. The 
level of significance was scaled to at least p < 0.05. 
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5. Results 
5.1 Validation of the quantitative PCR (qPCR) method 
In this study, the copy number data were obtained utilizing a qPCR method. Cycle 
number differences between primers for the nuclear single copy gene Kir4.1 and the 
mitochondrial DNA (mtDNA) were measured in qPCR reactions and subsequently 
analysed. A typical qPCR reaction for mtDNA determination is illustrated in figure 8. 
Triplicates of three different DNA concentrations for each primer were used. 
Assuming a comparable qPCR run, a difference of one cycle between the two 
different primers is equivalent to a twofold difference in copy number between the two 
compared genes. 
 
 
Figure 8. qPCR measurement for determination of the mtDNA copy number. Red – amplification with 
mtDNA primers, blue – amplification with nuclear primers, orange – threshold value provided by the 
qPCR thermocycler (table 6; table 8; paragraph 4.4.7). Three different DNA concentrations for each 
primer were used. 
 
The appropriateness of the qPCR method was verified with several controls. The 
detected cycle number difference can be influenced by several disturbing factors like 
a reduced primer quality. A suboptimal qPCR reaction could lead to an accordingly 
less efficient amplification of molecules and finally to an inaccurate copy number 
difference value. Therefore, the accuracy of the measured cycle difference of 
molecules amplified by the primers for the mtDNA and the nuclear single copy gene 
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Kir4.1 was measured indirectly by using a comparison between the single copy gene 
Kir4.1 and the low copy gene β-actin with already known copy number by database 
research. Performing an NCBI BLAST search, 13 hits for the β-actin region between 
the applied primers were found for the human genome (table 13). This fitted 
approximately to the measured β-actin copy number values of 11.53 ± 4.33 (n = 13) 
and 12.07 ± 2.21 (n = 6) copies in skeletal muscle and liver samples, respectively. In 
summary, one can say that the measured copy number difference between β-actin 
and Kir4.1 was similar to the copy number data for β-actin obtained by database 
research indicating the reliability of the qPCR method. 
 
Table 13. Hits from NCBI BLAST search for pseudogenes of gene-sequences from primer-amplified 
regions.  
Gene 
Reference hits for the 
amplified region 
Kir4.1 1 hit 
β-Actin 13 hits 
 
A reaction efficiency of 100 % corresponds to optimal qPCR conditions, which results 
in a doubling of DNA molecules in each cycle. Variations of this value are indicators 
of a suboptimal reaction. The efficiency of the reaction was determined in each 
reaction according to paragraph 4.4.7. Since all primers exhibited a nearly 100 % 
efficiency (table 14), they were qualified for use in qPCR. 
 
Table 14. Primer-dependent efficiency of qPCR reactions. 
Gene Primer-dependent  efficiency [%] 
Kir4.1 103 ± 14 
β-Actin 104 ± 10 
mtDNA 96 ± 10 
 
Furthermore, the influence of the DNA isolation method (paragraph 4.4.1-4.4.4) on 
the relation between the detectable single copy gene Kir4.1 and the mtDNA was 
examined. The comparison of different isolation techniques resulted in comparable 
values for the mtDNA copy number of wildtype fibroblasts (table 15) with 910 ± 209 
mtDNA copies for DNA isolation by salting out and 999 ± 213 mtDNA copies for DNA 
isolation by the QIAamp DNA Mini Kit. A student’s t-test (paragraph 4.6) revealed no 
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significant difference between the two DNA isolation methods. This led to the 
conclusion that the type of DNA isolation method had no effect on the ratio between 
mitochondrial and nuclear DNA. 
 
Table 15. Comparison of the influence of different DNA isolation methods on the mtDNA copy number 
using cultivated wildtype fibroblasts. 
Isolation method 
Number of 
samples 
mtDNA copy number 
DNA isolation by salting out 10 910 ± 209 
DNA isolation by the 
QIAamp DNA Mini Kit 
10 999 ± 213 
 
To estimate the linearity of the qPCR reaction, a dilution of a PCR fragment with a 
known concentration was performed. The measured cycle number was correlated to 
the PCR fragment copy number (figure 9). The leftmost and the rightmost points are 
corresponding to 1,000 and 16,284,000 PCR fragment molecules, respectively. A 
twofold higher concentration of the initial amount of DNA molecules resulted in an 
earlier qPCR signal, which was shifted by approximately one cycle. This indicates 
that the number of amplified molecules was doubled in each cycle underlining the 
linearity of this method. 
 
 
Figure 9. Illustration of the qPCR reaction in a linear regression curve. The initial amount of DNA 
molecules and the according cycle number data obtained by qPCR are correlated. The values are 
plotted in a semilogarithmic scale and represented with arithmetic mean and standard deviation. 
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The reliability of the qPCR measurement was further tested by comparing qPCR 
determinations of the mtDNA copy number in different mixtures of two cell lines 
exhibiting a different mtDNA copy number (figure 10). The selected cell lines were 
HeLa wildtype cells with a high mtDNA copy number and HeLa ρ0 cells containing 
mitochondria without mtDNA molecules in their matrix. The leftmost and the rightmost 
data points represent exclusively HeLa ρ0 and HeLa wildtype cells, respectively. 
HeLa ρ0 cells exhibited a measured copy number of  0.81 ± 0.12 mtDNA copies per 
nucleus. This error could either be caused by inaccuracy of the qPCR reaction, by a 
detected single copy nuclear pseudogene or by the background of unspecifically 
amplified products. The mtDNA copy number increased with ascending amount of 
HeLa wildtype cells up to 1,161 ± 228 mtDNA copies for pure HeLa wildtype cells. 
These data suggested a linearity of the correlation between measured cycle number 
difference and calculated mtDNA copy number values. 
 
 
Figure 10. mtDNA copy number of HeLa wildtype and HeLa ρ0 cells. Values are shown with arithmetic 
mean and standard deviation. 
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5.2 Tissue-specifity of the mtDNA content 
The mtDNA copy number values in different tissues and species had already been 
examined by several groups. However, the mtDNA content of several human tissues 
has not been compared in detail within one study. One scope of this study was the 
determination of the mtDNA copy number in several human tissues and cell types. 
These mtDNA copy number data should be subsequently compared with according 
mtDNA copy number values of patients affected by diseases related to mitochondrial 
defects. 
Therefore, data on the mtDNA copy number from several human tissues and cell 
types available for our group like skeletal muscle, brain specimen, liver, buccal 
mucosa, fibroblasts and blood were collected (paragraph 4.2.1; paragraph 4.2.2). 
Beside human tissues and cell types with ordinary occurrence and growth behaviour, 
the epithelial tumor HeLa cell line was used (paragraph 4.2.3). 
The mtDNA copy number was determined for control patients (figure 11; table 16) 
using the quantitative PCR (qPCR) method (paragraph 4.4.7). Patients suffering from 
mitochondrial diseases like mitochondrial encephalomyopathy, lactic acidosis and 
stroke-like episodes (MELAS) or myoclonic epilepsy with ragged red fibers (MERRF) 
(paragraph 2.6; paragraph 2.7) were not included. Material from children under three 
years was also not included since especially in blood specimen very young patients 
showed a high variation of the mtDNA copy number. For each control patient, at least 
triplicate experiments were performed each in three dilutions.  
 
Table 16. Content of mtDNA copies in human tissue samples. The values are represented with 
arithmetic mean and standard deviation, N – number of patients. 
Tissue Absolute mtDNA copy number  Age at sample delivery [years] Number [N] 
skeletal muscle 16,864 ± 8,843 21 ± 9  10 
brain 7,145 ± 4,086 34 ± 14 43 
liver 2,774 ± 1,153 47 ± 15 6 
buccal mucosa 1,294 ± 756 35 ± 13 16 
fibroblasts 961 ± 242 27 ± 16 8 
blood 283 ± 99  25 ± 17 22 
HeLa 1,161 ± 228 31 1 
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Figure 11. Comparison of the absolute mtDNA copy number in different tissues of control patients. 
Values are indicated with arithmetic mean and standard deviation. 
 
The obtained mtDNA copy numbers are tissue- and celltype-specific.  
 
5.3 Correlation between citrate synthase (CS) activity and mtDNA 
copy number in several tissues 
A couple of literature reports state on the one hand a tissue- and celltype-specific 
varying mitochondria content, which is ranging from about 100,000 mitochondria per 
oocyte (Ankel-Simons and Cummins, 1996; Chen et al., 1995) to four mitochondria 
per platelet (Shuster et al., 1988). Beside the strongly varying mitochondria content, 
the mtDNA content is reported to be between two and ten mtDNA molecules per 
mitochondrion (Graziewicz et al., 2006; Shuster et al., 1988; Wiesner et al., 1992).  
The mitochondria content and the mtDNA copy number were compared with each 
other in order to examine the stability of the ratio between the mitochondria and their 
DNA in different tissues. As a marker for the mitochondria content, CS is commonly 
used since it is regarded as a stably expressed enzyme located in the mitochondrial 
matrix (Figueiredo et al., 2008; Sarnat and Marín-García, 2005). 
Both the mtDNA copy number and the CS activity [µmol/(g⋅min)] were measured and 
subsequently compared (table 17). The citrate synthase (CS) assay procedure of 
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brain and muscle tissue specimen was performed by Alexey Kudin, PhD, from our 
group and Karin Kappes-Horn, Department of Neurology, University Bonn. 
The determination of the CS activity was performed in triplicates for each patient. The 
CS activity was normalised to the protein content referring to equal amounts of cell 
mass. Since the protein content in muscle tissue was firstly determined in g wet 
weight, the unit g wet weight was afterwards transformed to g protein with the factor 
0.08 [g protein / g wet weight] for muscle tissue (Maia et al., 2005).  
The CS activity was ranging from 32 ± 10 µmol/(g·min) in buccal mucosa to 195 ± 30 
µmol/(g·min) in brain specimen. The mtDNA depleted HeLa ρ0 cells had a marginally 
higher CS activity than HeLa wildtype cells with a high mtDNA content. The 
difference in the CS activity can possibly be related to a compensatory effect. This 
led to the conclusion that the mitochondrial content in HeLa cells was not severely 
affected by the amount of mtDNA. 
 
The measured CS values resembled to available data in literature (Barthélémy et al., 
2001; Gellerich et al., 2002; Kudin et al., 2002; Sarnat and Marín-García, 2005). 
The ratio of the mtDNA content to the CS activity obtained values, which range from 
14 to 35 for most examined tissues and cell types. In contrast to these similar ratio 
values, HeLa ρ0 cells, containing only 0.81 ± 0.12 mtDNA copies, exhibited a low 
ratio of 0.01. This ratio resulted from the fact that HeLa ρ0 cells contain mitochondria 
depleted of their DNA. On the contrary, in skeletal muscle fibers a high ratio of 109 
was detected. This unexpected high value could be caused by a high accumulation 
of mtDNA molecules in mitochondria compared to the mitochondrial volume. Possible 
reasons for this peculiarity could lie in the muscle specific mitochondrial morphology 
or tasks. 
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Table 17. Correlation between mtDNA content and CS activity. The values are represented with 
arithmetic mean and standard deviation, N – number of patients. 
Tissue/cell 
type 
CS activity 
[µmol/(g·min)] 
Absolute 
mtDNA copy 
number 
Age at sample 
delivery [years] 
Number 
[N] 
mtDNA copy 
number/CS activity 
skeletal muscle 166 ± 36 17,999 ± 9,296 19 ± 10 8 109 
brain 195 ± 30 6,728 ± 3,991 21 ± 12 10 35 
buccal mucosa 32 ± 10 954 ± 353 36 ± 7 10 30 
fibroblasts 68 ± 7 961 ± 242 27 ± 16 8 14 
HeLa wildtype 64 ± 2 1,161 ± 228 31 1 18 
HeLa ρ0 92 ± 1 0.81 ± 0.12 31 1 0.01 
 
5.4 mtDNA depletion in blood specimen of patients with a mild 
phenotype of PEO with epilepsy/ataxia  
Mutations in the nuclear encoded polymerase γ gene POLG are known to cause a 
variety of mitochondrial disease phenotypes including progressive external 
ophthalmoplegia (PEO) (Graziewicz et al., 2006). PEO is characterized by multiple 
deletions and mutations in the mitochondrial genome (Cardaioli et al., 2007; 
Spinazzola and Zeviani, 2005; Zeviani et al., 1989). It still remains to be elucidated 
how the nuclear POLG genotype influences the corresponding mitochondrial 
phenotype. We were especially interested if a reduction of mtDNA molecules within 
the mitochondria has, beside the existing deleted mtDNA molecules, an influence on 
the appearance of the disease. A family with hereditary pathogenic mutations 
provided us the opportunity to examine this correlation. 
The total DNA content of blood specimen from a family with three daughters, two of 
them affected by several neurological symptoms like epilepsy, ataxia and neuropathy 
as well as a mild phenotype of PEO, was analysed for frequent mutations in the 
polymerase γ gene POLG (paragraph 2.7; paragraph 2.8; Paus et al., 2008). The 
DNA mutation analysis of this family was performed using restriction fragment length 
polymorphism (RFLP) analysis of PCR fragments by Gábor Zsurka, MD, PhD and 
Ulrike Strube, Departments of Epileptology and Neurology, University Bonn. 
The healthy father harboured the heterozygous A467T POLG mutation, the healthy 
mother the heterozygous POLG mutation W748S in cis with the polymorphism 
E1143G (figure 12). Daughter two possessed the same POLG variations like the 
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mother and showed no symptoms characteristic for a mitochondrial disease. 
However, the daughters one and three featured the combination of the three DNA 
variations W748S and E1143G compound heterozygous with A467T (figure 12). 
These daughters developed the described symptoms of a mitochondrial disease 
(Paus et al., 2008). Since the mutation W748S and the polymorphism E1143G were 
generally found together (Chan et al., 2006; Hakonen et al., 2005; Nguyen et al., 
2005; Van Goethem et al., 2004), this suggests that both rearrangements segregate 
together on the same allele. 
 
 
Figure 12. POLG genotyping of a family with members affected by a mild phenotype of PEO with 
epilepsy/ataxia. wt = wildtype, mt = mutant. 
 
The mtDNA copy number values of blood samples from this family were compared to 
blood samples from age-matched controls (figure 13; table 18). The healthy father 
and the healthy daughter two exhibited mtDNA copy number values being within the 
range of the population of control blood samples. However, the mtDNA copy 
numbers in blood samples of both daughters, which were affected by the mild 
phenotype of PEO with epilepsy/ataxia, as well as the healthy mother are significantly 
decreased in a student’s t-test with p < 0.001 in comparison to the controls. In 
particular, the mtDNA copy number content decreased to 69 % for the mother, to 50 
% for daughter one and to 38 % for daughter three.  
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Table 18. Nuclear and mitochondrial features of patients with a mild phenotype of PEO with 
epilepsy/ataxia (modified from Paus et al., 2008). N – number of patients, n - number of experiments. 
Values are indicated with arithmetic mean and standard deviation, *** p < 0.001. 
Relation Control Mother Father Daughter 1 Daughter 2 Daughter 3 
pathogenic 
POLG 
mutations 
 
E1143G + 
W748S 
A467T 
E1143G + 
W748S / 
A467T 
E1143G + 
W748S 
E1143G + 
W748S / 
A467T 
 N n n n n n 
number  22 36 27 36 27 36 
mtDNA copy 
number 
283 ± 99 194 ± 35*** 289 ± 53 141 ± 22*** 245 ± 63 108 ± 41*** 
mtDNA content 
variation 
referring to 
control 
population [%] 
 69 102 50 87 38 
age at sample 
delivery [years] 25 ± 17 64 64 37 38 39 
 
 
Figure 13. Comparison of the mtDNA copy number in blood specimen of controls and a family with 
members affected by a mild phenotype of PEO with epilepsy/ataxia (daughter one and three). Values 
are indicated with arithmetic mean and standard deviation, *** p < 0.001. 
 
Concluding, we found a combined occurrence of a specific nuclear POLG genotype 
and a depletion of mtDNA in blood specimen of family members affected by a mild 
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phenotype of PEO with epilepsy/ataxia. Additionally, PEO is accompanied by the 
occurrence of large deletions within the mitochondrial genome. Multiple deletions 
were in fact detected previously by DNA mutation analysis in muscle tissue samples 
of both affected daughters (Paus et al., 2008). The heteroplasmic ratio of wildtype 
and deleted mtDNA molecules in the tissues of the affected patients might 
additionally enhance the severity of the clinical phenotype. 
 
5.5 mtDNA depletion in patients with Alpers-Huttenlocher syndrome  
Another well-known mitochondrial disease due to a mutation in the POLG gene is the 
Alpers-Huttenlocher syndrome. Patients with this syndrome show myoclonic epilepsy 
and several other symptoms such as seizures, psychomotor regression and 
valproate induced liver failure (paragraph 2.7). The Alpers-Huttenlocher syndrome is 
apart from severe mtDNA depletion accompanied by alterations of the mitochondrial 
genome like multiple deletions and certain point mutations (Ashley et al., 2008; 
Naviaux et al., 1999; Zsurka et al., 2008). The opportunity to examine to which 
extend several tissues exhibit a mtDNA copy number reduction was given. 
Furthermore, the importance of the mtDNA copy number reduction in comparison to 
mtDNA deletions was investigated.   
 
The clinical features of five paediatric patients were examined (table 19; Zsurka et al., 
2008). However, two patients showed no liver failure supposably due to the early 
diagnosis of the mitochondrial disease phenotype associated with the corresponding 
pathogenic POLG mutations.  
The DNA mutation analysis of the five patients was performed using restriction 
fragment length polymorphism (RFLP) analysis of PCR fragments by Gábor Zsurka, 
MD, PhD and Ulrike Strube, Departments of Epileptology and Neurology, University 
Bonn. In these patients, several well-known POLG mutations have been detected 
with some of them occurring in a compound heterozygous way (table 19). 
Additionally to these well-known exonic POLG changes, several intronic variations as 
well as variations in the polyglutamine repeat of exon two were detected. These 
variations were so far not correlated to any known mitochondrial disease phenotype. 
Aside from the examination of nuclear changes on POLG, the patients were tested 
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for deletions within the mitochondrial DNA. They exhibited only a very low amount of 
deleted molecules (Zsurka et al., 2008). 
 
Table 19. Genetic background and phenotype of patients with Alpers-Huttenlocher syndrome 
(according to Zsurka et al., 2008). p – patient. Single nucleotide polymorphisms (SNPs) marked in 
italic - coding region mutations numbered by amino acid positions. Non-marked SNPs – intronic 
mutations (accession no. NC_000015.8, region 87660554-87679030). 
Patient 
Age at 
sample 
delivery 
[years] 
Clinical phenotype  
Pathogenic 
POLG mutations 
POLG SNPs 
p1 8; 17 
epilepsia partialis 
continua; valproate 
induced liver failure 
(† at 17 years) 
A467T/A467T 
del11751CGCGTGCG/ 
del11751CGCGTGCG 
p2 16 
epilepsia partialis 
continua; valproate 
induced liver failure 
A467T/F749S 
del43QQQ/wt; C9078T/wt; 
del11751CGCGTGCG/del11751CGC
GTGCG; ins13710GTAG/wt; 
C13769T/wt; del15681GT/wt; 
T17677G/wt 
p3 4 
prolonged status 
epilepticus; elevated 
lactate and protein 
in cerebrospinal fluid 
A467T/G848S del11751CGCGTGCG/wt 
p4 7 
complex partial 
seizures; migraine; 
valproate induced 
liver failure  
(† at 10 years) 
W748S+E1143G/ 
L752P 
C11741T/wt 
p5 4 
epilepsia partialis 
continua 
W748S+E1143G/ 
G848S 
ins53Q/wt; G1791T/wt; T10873C/wt; 
T11073C/wt; C11741T/wt; 
ins13710GTAG/wt; 
A15661G/wt;T15686C/wt; 
T17241G/wt; 
G17600A/wt;T17677G/wt 
 
The mtDNA copy number in several tissues of these patients was measured. For 
each control, at least triplicate experiments were performed each in three dilutions. 
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The particular number of experiments performed for the respective Alpers-
Huttenlocher patients are listed in table 20. 
For patient one, samples from biopsies at the age of eight and 17 years (post 
mortem) were available. All examined patient tissues exhibited lowered mtDNA copy 
numbers compared to the controls (figure 14; table 19; table 20; Zsurka et al., 2008). 
In all five patients affected by Alpers-Huttenlocher syndrome, the reduction of the 
mtDNA copy number compared to the controls was significant in a student’s t-test (p 
< 0.05 – p < 0.001).  
At the age of eight years, the mtDNA copy number of patient one was reduced to 
values of 52 % and 37 % of the corresponding control values in skeletal muscle and 
blood, respectively. At the age of 17 years, the copy number in skeletal muscle was 
lowered further to 15 % of the according control value. In the other examined post 
mortem tissues, a reduction of the mtDNA copy number to 75 % for brain and 11 % 
for liver compared to the controls was measured. Patient two showed a lowered 
mtDNA copy number of 25 % and 45 % in skeletal muscle and blood, respectively. 
The mtDNA copy number values of patients three and four in blood were reduced 
similarly to 33 % and 34 %, respectively (table 20). Patient five suffering from a 
milder manifestation of the disease (table 19), exhibited likewise a lowered mtDNA 
copy number, which was only slightly decreased with mtDNA copy number values of 
51 % in skeletal muscle and 54 % in blood (table 20).  
The findings of a mtDNA copy number reduction in all examined tissues of the 
Alpers-Huttenlocher patients matched well to depletion data from the literature 
regarding this disease (Ashley et al., 2008; Naviaux et al., 1999). 
Additionally to the decreased mtDNA copy number values in all patients exhibiting 
the biochemical and clinical phenotype, deleted mtDNA molecules were detected 
(Zsurka et al., 2008). However, since the amount of the deleted molecules was very 
low, a significant contribution to the disease phenotype is very unlikely.   
 
 
 
 
 
 
 
Results 49
Table 20. Depletion in various tissues of patients with Alpers-Huttenlocher syndrome (modified from 
Zsurka et al., 2008). N – number of patients, n - number of experiments, p - patient; Values are 
represented with arithmetic mean and standard deviation, * p < 0.05, ** p < 0.01, *** p < 0.001.  
Patient 
Age at sample 
delivery [years] 
Skeletal 
muscle 
Brain Liver Blood 
controls 
for age of 
controls refer to 
table 16 
16,864 ± 8,843 
(N = 10) 
7,145 ± 4,086 
(N = 43) 
2,774 ± 1,153 
(N = 6) 
283 ± 99 
(N = 22) 
p 1 8 
8,799 ± 1,760* 
(n = 36) --- --- 
105 ± 13***  
(n = 27) 
p 1 17 
2,564 ± 654*** 
(n = 54) 
5,349 ± 671** 
(n = 27) 
317 ± 111**  
(n = 45) --- 
p 2 16 
4,208 ± 809** 
(n = 54) --- --- 
126 ± 16*** 
(n = 3) 
p 3 4 --- --- --- 
92 ± 22*** 
(n = 27) 
p 4 7 --- --- --- 
96 ± 22***  
(n = 12) 
p 5 4 
8,606 ± 940* 
(n = 9) --- --- 
153 ± 33***  
(n = 36) 
 
 
Figure 14. Depletion in blood samples of patients with Alpers-Huttenlocher syndrome (modified from 
Zsurka et al., 2008). p – patient. Values are indicated with arithmetic mean and standard deviation, *** 
p < 0.001. 
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The liver tissue of patient one, who died from valproate induced liver failure, was also 
examined histochemically. Tissue slices of post mortem liver were double stained for 
cytochrome c oxidase (COX, red staining) and succinate dehydrogenase (SDH, blue 
staining) activity (figure 15; paragraph 4.5.4). The COX and SDH activity staining of 
the slices was performed by Karin Kappes-Horn, Department of Neurology, 
University Bonn. A pattern of large COX negative (COX-) and small COX positive 
(COX+) areas was visualised indicating a pattern of regions with different mtDNA 
background resulting in intact and defect mitochondria.  
 
 
Figure 15. COX-SDH double staining of liver slices (modified from Zsurka et al., 2008). Red areas – 
COX+, blue areas – COX-. Left – COX+ and COX- areas of patient one featuring Alpers-Huttenlocher 
syndrome, right – control patient, low – higher magnification of a section of patient one liver. 
 
The stained liver slices were microdissected to get cells from areas with different 
COX background. The obtained cells were examined for their mtDNA content 
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(paragraph 4.4.4). The mtDNA copy number in patient one was significantly (p < 
0.01) higher in COX+ regions possessing an almost fivefold higher mtDNA content 
with 716 ± 247 mtDNA copies compared to COX- regions exhibiting 155 ± 59 mtDNA 
copies (figure 16; table 21). These mtDNA copy number values correspond to the 
COX staining differences observable in histological liver slices. 
 
Table 21. mtDNA copy number distribution in liver regions of patient one (p1). Values are indicated 
with arithmetic mean and standard deviation, n – number of experiments. 
Tissue area mtDNA copy number 
total 317 ± 111 (n = 45) 
COX+  716 ± 247 (n = 6) 
COX-  155 ± 59 (n = 11) 
 
 
Figure 16. Mitochondrial dysfunction in COX+ and COX- regions of postmortem liver of patient one 
(p1) featuring Alpers-Huttenlocher syndrome (modified from Zsurka et al., 2008). Values are 
represented with arithmetic mean and standard deviation, ** p < 0.01.  
 
5.6 Reduction of the mtDNA copy number in specific brain regions 
from Ammon’s horn sclerosis (AHS) patients 
The neurological disease temporal lobe epilepsy (TLE) with Ammon’s horn sclerosis 
(AHS) is accompanied by the occurrence of status epilepticus, which is known to 
activate neuronal cell death mechanisms occurring mainly in the hippocampal cornu 
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ammonis 1 (CA1) and cornu ammonis 3 (CA3) neurons (Baron et al., 2007; Ben-Ari 
et al., 1980; Kunz et al., 2000; Liu et al., 1994; Liu et al., 1995; Nadler, 1981). An 
elevated level of reactive oxygen species (ROS) can be detected during status 
epilepticus (Kovacs et al., 2001; Liang et al., 2000). It is an important question, how 
changes in the function of mitochondria and the mtDNA level can affect this disease. 
Several areas of hippocampal brain specimen from control patients with lesion as 
well as patients affected by TLE with AHS were examined with regard to their mtDNA 
content (figure 17; table 22; Baron et al., 2007). The control patients exhibited only a 
lesional damage of the brain tissue close to the hippocampus (e. g. parahippocampal 
tumor), which is not causing neuronal cell death in the hippocampus. For each 
patient, at least triplicate experiments were performed each in three dilutions. The 
different hippocampal regions of patients with lesions or AHS are compared with a 
two-sided paired t-test.  
The mtDNA copy number of AHS patients in the areas area dentata (AD) and 
parahippocampus (PH) was, in comparison to the lesion patients, only mildly reduced 
to 92 % and 94 % in AD and PH, respectively. However, this difference was not 
significant.  
The other examined regions of the hippocampus, namely CA1 and CA3, showed a 
significant reduction to 47 % (p < 0.01) and 56 % (p < 0.05) of the control value, 
respectively. The reduction of the mtDNA content is in accordance to depletion data 
reported for CA1 and CA3 in rat hippocampus (Kudin et al., 2002). Furthermore, 
changes in these hippocampal regions are accompanied by both an impaired 
respiratory chain (Kudin et al., 2002; Kunz et al., 2000) and a reduction of the 
mitochondrial marker enzyme citrate synthase (CS) (Baron et al., 2007). These 
combined findings indicate an influence of the mtDNA copy number on the 
mitochondrial activity in CA1 and CA3 neurons. 
 
Table 22. mtDNA copy number in hippocampal subfields of patients afflicted by temporal lobe epilepsy 
(TLE). Values are indicated with arithmetic mean and standard error, N – number of patients, * p < 
0.05, ** p < 0.01. AHS – Ammon’s horn sclerosis, CA1 – cornu ammonis 1, CA3 – cornu ammonis 3, 
AD – area dentata, PH – parahippocampus. 
Subfield CA1 AD CA3 PH 
lesion (N = 11) 8,758 ± 1,266 7,062 ± 975 6,001 ± 1,067 6,601 ± 1,149 
AHS (N = 22) 4,131 ± 656** 6,474 ± 1,214 3,361 ± 380* 6,173 ± 773 
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Figure 17. mtDNA copy number in hippocampal subfields of patients affected by temporal lobe 
epilepsy (TLE) (modified from Baron et al., 2007). AHS – Ammon’s horn sclerosis, CA1 – cornu 
ammonis 1, CA3 – cornu ammonis 3, AD – area dentata, PH – parahippocampus. Values are 
indicated with arithmetic mean and standard error, * p < 0.05, ** p < 0.01, N (lesion) = 11, N (AHS) = 
22.  
 
5.7 Influence of the mtDNA content on the mitochondrial respiration 
activity 
In several mitochondrial diseases, a threshold linked to bioenergetic defects and 
accordingly the clinical phenotype is postulated. This threshold refers to the 
heteroplasmic state of the cell and is specific for the respective mtDNA mutation 
(Rossignol et al., 2003). The bioenergetical context, in which this threshold occurs, 
has not been elucidated completely.  
The described effect was examined in fibroblasts using an in vitro assay, in which 
cells were treated with 2’, 3’-dideoxycytidine (ddC) or ethidium bromide (EtBr) to 
deplete their mtDNA. Depletion studies using ddC or EtBr have already been 
performed by other groups (Brown and Clayton, 2002; Chen and Cheng, 1989; Diaz 
et al., 2002; King and Attardi, 1989; Maniura-Weber et al., 2004; Martin et al., 1994; 
Miller et al., 1996; Pan-Zhou et al., 2000; Piechota et al., 2006a; Trounce et al., 1994; 
Zimmermann et al., 1980). EtBr intercalates between the bases of the DNA and 
hence inhibits the replication leading to a depletion. ddC is integrated into the DNA 
causing termination of strand elongation and therefore inhibits the replication as well. 
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Cultured skin fibroblasts of a 38 year old control patient were treated with EtBr or ddC 
for 25 days (paragraph 4.3.4). The treatment with these substances resulted each in 
a decrease of the mtDNA copy number (figure 18). In comparison to the wildtype 
cells with 563 ± 277 mtDNA copies, the number decreased to 1.74 ± 0.34 mtDNA 
copies (0.31 %) and 32 ± 4 mtDNA copies (5.65 %) in ddC- (figure 18A) and EtBr-
treated cells (figure 18B), respectively. To proof the significance of the mtDNA 
reduction, a univariate variance analysis (ANOVA) was performed. The first 
significant difference, specified further in a following Dunnett test, appeared at day 
three of ddC-treatment and at day six of EtBr-treatment (figure 18). The significance 
strengthened during the further course of treatment. For each specific timepoint three 
measurements of independent samples were performed  (n = 3).  
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Figure 18. mtDNA depletion in ddC- and EtBr-treated fibroblasts. Measurement of mtDNA copy 
number changes in ddC- (A) and EtBr-treated (B) skin fibroblasts. Values are represented with 
arithmetic mean (n = number of experiments, = 3) and standard deviation, * p < 0.05. 
 
Additionally to the mtDNA copy number, the citrate synthase (CS) activity was 
measured to correlate the mtDNA copy number to the mitochondrial content (figure 
19). The CS activity was normalised to the protein content referring to equal amounts 
of cell mass. Wildtype fibroblasts showed a CS activity of 55 ± 4 µmol/(g⋅min). After 
25 days of treatment, the cells featured a CS activity of 65 ± 5 µmol/(g⋅min) for ddC 
(figure 19A) and 63 ± 16 µmol/(g⋅min) for EtBr, respectively (figure 19B). The 
A
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enzymatic activity of wildtype and treated cells showed no significant difference in an 
one-way ANOVA followed by Dunnett test. For each specific timepoint, three 
measurements were performed in triplicates (n = 3). In spite of the depletion 
treatment, the mitochondria content of the cells stayed stable. This indicated that 
there was no loss of mitochondria but only of their mtDNA. 
 
 
 
Figure 19. Detection of CS activity in ddC- (A) and EtBr-treated (B) fibroblasts. Values are indicated 
with arithmetic mean (n = number of experiments, = 3) and standard deviation. 
 
During the depletion treatment the respiratory activity of the fibroblasts was 
measured using an oxygraph (figure 20; figure 21; table 6; table 8; paragraph 4.5.3). 
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The respiratory activity was measured in order to examine both if the depletion had 
an influence on the bioenergetic state of the cells and how the correlation between 
mtDNA depletion and the onset and severity of the bioenergetic impairment would 
be.  
 
 
Figure 20. Complex I-dependent respiration of fibroblasts. Blue – oxygen concentration [nmol/ml], red 
– first derivative [pmol/(s·ml)]. A – wildtype fibroblasts, B – 25 days treatment with 2’, 3’-
dideoxycytidine (ddC), C – 25 days treatment with ethidium bromide (EtBr). Cells – addition of 
A
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fibroblasts to the chamber, digitonin – permeabilization with digitonin, ADP – stimulation with ADP, 
glutamate – substrate for complex I, TTFB-1 up to TTFB-3 – stepwise addition of the toxic uncoupler 
TTFB for stimulation of the respiratory chain. 
 
 
Figure 21. Complex II-dependent respiration of fibroblasts. Blue – oxygen concentration [nmol/ml], red 
– first derivative [pmol/(s·ml)]. A – wildtype fibroblasts, B – 25 days treatment with 2’, 3’-
dideoxycytidine (ddC), C – 25 days treatment with ethidium bromide (EtBr). Cells – addition of 
fibroblasts to the chamber, succinate – substrate for complex II, digitonin – permeabilization with 
C
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digitonin, ADP – stimulation with ADP, TTFB-1 up to TTFB-3 – stepwise addition of the toxic uncoupler 
TTFB for stimulation of the respiratory chain. 
 
The respiratory activity of the fibroblasts was measured at specific time points of the 
depletion treatment. During these respiratory measurements, the basic respiration of 
the cells, the ADP-stimulated respiration as well as the TTFB-uncoupled respiration 
were recorded (figure 22-25). Both in ddC- and EtBr-treated fibroblasts, the complex 
I- and complex II-dependent  respiratory activity itself (figure 22A-25A) as well as the 
ability of the cells to be stimulated by ADP (figure 22B-25B) and TTFB (figure 22C-
25C) decreased. This decrease was proved to be significant in an ANOVA for all 
treatments.  
 
The respiratory activity depending on complex I was determined by a measurement 
using pyruvate and malate as substrates (figure 20). Furthermore, glutamate, a 
further complex I-dependent substrate, was added to exclude a direct influence of 
pyruvate dehydrogenase on the respiration (paragraph 4.5.3). However, bypassing 
pyruvate dehydrogenase with glutamate resulted in no significant changes. 
Initially, the ddC-treated fibroblasts showed a milder decrease of the respiratory 
activity compared to the EtBr-treated fibroblasts (figure 22; figure 23; table 23; table 
24). This milder course of the decrease can be exemplified at day ten. At this point of 
time, the respiratory activity had fallen stronger in EtBr- than in ddC-treated cells.  
Likewise, the significance of this reduction appeared earlier in EtBr- than in ddC-
treated cells. In ddC-treated cells, a significance starting at day ten for ADP-
stimulated respiration and at day 15 for basic and TTFB-uncoupled respiration was 
found in an ANOVA with adjacent Dunnett test. However, in EtBr-treated cells a 
statistical difference appeared earlier at day four for ADP-stimulated, at day five for 
TTFB-uncoupled and at day six for basic respiration. The statistical difference 
strengthened both for ddC- and EtBr-treated cells over the further course of the 
experiment (table 23; table 24).  
The treatment was extended in order to examine, to which extent the respiratory 
activity could be minimized in living fibroblasts. During the ongoing treatment, the 
basic, the ADP-stimulated and the TTFB-uncoupled respiration were almost equal, 
which is illustrated by the very similar course of the respiration curves (figure 20; 
figure 21). At day 25 of the treatment, the fibroblasts showed a similar basic 
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respiratory activity in ddC- and EtBr-treated cells of 12 % and 5 % compared to the 
controls, respectively (table 23; table 24).   
 
Table 23. Measurement of the respiratory activity depending on complex I of ddC-treated fibroblasts. 
Values are represented with arithmetic mean (number of experiments - n = 3) and standard deviation, 
* p < 0.05, ***  p < 0.001. 
  Wildtype 10 d ddC 25 d ddC 
[nmol O2/(min·mg prot)] 7.91 ± 1.59 5.25 ± 0.88 0.93 ± 0.72*** Basic respiration 
[%] 100 66 12 
[nmol O2/(min·mg prot)] 10.92 ± 1.85 4.90 ± 1.15* 0.53 ± 0.56*** ADP-stimulated 
respiration [%] 100 45 5 
[nmol O2/(min·mg prot)] 14.63 ± 3.84 6.93 ± 1.90 1.02 ± 0.51*** TTFB-uncoupled 
respiration [%] 100 47 7 
 
Table 24. Measurement of the respiratory activity depending on complex I of EtBr-treated fibroblasts. 
Values are represented with arithmetic mean (number of experiments - n = 3) and standard deviation, 
**  p < 0.01, ***  p < 0.001. 
  Wildtype 10 d EtBr 25 d EtBr 
[nmol O2/(min·mg prot)] 7.91 ± 1.59 2.41 ± 0.44** 0.39 ± 0.03*** Basic respiration 
[%] 100 30 5 
[nmol O2/(min·mg prot)] 10.92 ± 1.85 1.91 ± 0.41*** 0.64 ± 0.08*** ADP-stimulated 
respiration [%] 100 17 6 
[nmol O2/(min·mg prot)] 14.63 ± 3.84 4.05 ± 1.36** 0.69 ± 0.50*** TTFB-uncoupled 
respiration [%] 100 28 5 
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Figure 22. Complex I-dependent respiratory activity in ddC-treated fibroblasts. Basic respiratory 
activity (A), stimulation with ADP (B), uncoupling with TTFB (C). Values are represented with 
arithmetic mean (number of experiments - n = 3) and standard deviation, * p < 0.05. 
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Figure 23. Complex I-dependent respiratory activity in EtBr-treated fibroblasts. Basic respiratory 
activity (A), stimulation with ADP (B), uncoupling with TTFB (C). Values are represented with 
arithmetic mean (number of experiments - n = 3) and standard deviation, * p < 0.05. 
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The complex II-dependent measurements were performed by application of succinate 
combined with rotenone addition causing complex I inhibition (figure 21). The 
depletion dependent respiratory inhibition shown in former experiments was reflected 
in a milder way also in the complex II-dependent respiration (figure 24; figure 25; 
table 25; table 26). This milder inhibition could be a result from the lower amounts of 
mtDNA encoded proteins involved in this reaction. 
Like for complex I-dependent respiration, the reduction of the respiratory activity 
proceeded faster in EtBr-treated cells. The respiratory activity at day ten can be 
presented as an example. At that point of time, the respiratory activity of ddC-treated 
cells had fallen to 89 % of the control value (table 25). However, EtBr-treated cells 
exhibited an impairment of their activity to 65 % (table 26). 
Also the significance of this reduction increased earlier in EtBr-treated cells. In ddC-
treated cells, a significant difference from the control value was detectable starting 
from day 15 of the treatment persisting over the further progression of the experiment 
(figure 24). However, in EtBr-treated cells, a significant reduction was detected 
starting from day four for ADP-stimulated, day seven for TTFB-uncoupled and day 20 
for basic respiration, remaining during the further progress of the experiment (figure 
25). 
The treatment was extended in order to examine, to which value the respiratory 
activity of living fibroblasts could be minimized under this conditions. The complex II- 
dependent respiratory activity decreased in ddC- and EtBr-treated cells down to 28 % 
and 25 % of the control value, respectively (table 25; table 26). Likewise to the 
measurement regarding complex I-dependent respiratory activity, the course of the 
graphic respiration curves reached a relatively stable level in the final phase of the 
experiment (figure 24; figure 25).  
 
One can conclude that, although the complex I- and the complex II-dependent 
respiratory activity decreased strongly both in ddC- and EtBr-treated cells (figure 22-
25; table 23-26), this respiratory inhibition became manifest faster in EtBr-treated 
cells (figure 23; figure 25; table 24; table 26). The respiratory activity indicates the 
bioenergetic state of the fibroblasts. A possible reason for the faster impairment of 
the respiration during EtBr-induced depletion could lie in the toxic side effects of EtBr 
like an impairment of transcription and translation (Hayashi et al., 1990; Maniura-
Weber et al., 2004; Tønnesen and Friesen, 1973; Zylber et al., 1969). 
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Table 25. Measurement of the respiratory activity depending on complex II of ddC-treated fibroblasts. 
Values are represented with arithmetic mean (number of experiments - n = 3) and standard deviation, 
**  p < 0.01, ***  p < 0.001. 
  Wildtype 10 d ddC 25 d ddC 
[nmol O2/(min·mg prot)] 3.44 ± 0.76 3.07 ± 0.80 0.97 ± 0.65** Basic respiration 
[%] 100 89 28 
[nmol O2/(min·mg prot)] 12.25 ± 2.15 8.45 ± 2.63 1.06 ± 0.68*** ADP-stimulated 
respiration [%] 100 69 9 
[nmol O2/(min·mg prot)] 12.46 ± 2.67 10.57 ± 1.93 2.12 ± 1.38*** TTFB-uncoupled 
respiration [%] 100 85 17 
 
Table 26. Measurement of the respiratory activity depending on complex II of EtBr-treated fibroblasts. 
Values are represented with arithmetic mean (number of experiments - n = 3) and standard deviation, 
* p < 0.05, ***  p < 0.001. 
  Wildtype 10 d EtBr 25 d EtBr 
[nmol O2/(min·mg prot)] 3.44 ± 0.76 2.22 ± 0.39 0.87 ± 0.07* Basic respiration 
[%] 100 65 25 
[nmol O2/(min·mg prot)] 12.25 ± 2.15 2.47 ± 0.52*** 0.77 ± 0.15*** ADP-stimulated 
respiration [%] 100 20 6 
[nmol O2/(min·mg prot)] 12.46 ± 2.67 5.50 ± 1.58* 0.87 ± 0.41*** TTFB-uncoupled 
respiration [%] 100 44 7 
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Figure 24. Complex II-dependent respiratory activity in ddC-treated fibroblasts. Basic respiratory 
activity (A), stimulation with ADP (B), uncoupling with TTFB (C). Values are indicated with arithmetic 
mean and standard deviation, * p < 0.05. 
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Figure 25. Complex II-dependent respiratory activity in EtBr-treated fibroblasts. Basic respiratory 
activity (A), stimulation with ADP (B), uncoupling with TTFB (C). Values are indicated with arithmetic 
mean and standard deviation, * p < 0.05. 
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The depletion of the mtDNA is the direct cause for the respiratory impairment of the 
cells. However, the depletion and the respective respiratory impairment could have 
either a linear or a logarithmic relationship to each other. A linear correlation hints to 
a proportional decrease, whereas a logarithmic correlation is a sign of a threshold. 
The respiratory activity would then be relatively stable above this threshold point, but 
would show a sharp decline below. 
The maximal respiratory activity resulting from TTFB-uncoupling was plotted against 
the mtDNA copy number (figure 26; figure 27). The correlation of respiration and 
mtDNA copy number measured during the ddC-treatment shows the logarithmic 
relationship both for complex I- and complex II-dependent respiratory activity (figure 
26). This indicates a threshold for the relation between respiration and mtDNA 
content.  
The threshold was calculated as a halfmaximal value of the mtDNA copy number out 
of a logarithmic regression provided by SigmaPlot 2001 (table 9) with the following 
cubic function: 
 
y y0 a lnx b lnx
2
c lnx 3
 
 
The four parameters y0, a, b and c are scalars describing the shape of the curve. 
The possible solutions for x were calculated by Cardano’s method. The half maximal 
y value was used to calculate the according x value for the mtDNA threshold referring 
to increasing bioenergetic consequences. 
 
A half maximal value (xmax/2) of 23.90 mtDNA copies is achieved with the correlation 
with the complex I-dependent respiratory activity (figure 26A). The correlation with 
the complex II-dependent respiratory activity leads to xmax/2 of 7.06 mtDNA copies 
(figure 26B). According to these results, a mtDNA copy number of approximately 24 
and seven copies per nucleus would be necessary for a stable complex I- and II-
dependent respiration, respectively. The existence of the threshold could possibly 
originate from a superabundance of mtDNA copies in intact cells. 
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Figure 26. Correlation of mtDNA copy number and respiratory activity for ddC-treated fibroblasts. The 
mtDNA copy number is correlated with the maximal complex I- (A) respectively complex II- (B) 
dependent respiratory activity after TTFB-uncoupling. Values are represented with arithmetic mean 
and standard deviation. 
 
A plotting of the respiratory activity after TTFB-uncoupling against the mtDNA copy 
number was performed likewise for EtBr-treated cells (figure 27). However, the 
complex I- and II-dependent respiratory activity values taken during the EtBr-
treatment showed a linear relationship. This linear relationship could be based on the 
toxic side effects of EtBr like an impairment of transcription and translation (Hayashi 
B
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et al., 1990; Maniura-Weber et al., 2004; Tønnesen and Friesen, 1973; Zylber et al., 
1969) leading to a faster reduction of the respiratory activity of the fibroblasts. 
 
 
 
Figure 27. Correlation of mtDNA copy number and respiratory activity for EtBr-treated fibroblasts. The 
mtDNA copy number is correlated with the maximal complex I- (A) respectively complex II- (B) 
dependent respiratory activity after TTFB-uncoupling. Values are indicated with arithmetic mean and 
standard deviation. 
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6. Discussion 
6.1 Effect of mtDNA depletion on the bioenergetic status of the cell 
Mitochondria contain their own DNA (mtDNA) that encodes for 13 protein subunits of 
the oxidative phosphorylation system (OXPHOS). A reduction of the mtDNA content, 
i.e. mtDNA depletion, can lead to a decreased energy production and consequently 
to bioenergetic problems within the cell.  
In literature reports, an artificial reduction of the mtDNA copy number has been 
already described, but the effect on the bioenergetic status has not been studied in 
great detail. MtDNA depletion was generated using ethidium bromide (EtBr) in the 
majority of studies (Diaz et al., 2002; King and Attardi, 1989; Maniura-Weber et al., 
2004; Miller et al., 1996; Piechota et al., 2006a; Trounce et al., 1994). A prominent 
example for a cell line successfully depleted with EtBr are the so called ρ0 cells, 
which completely lack mtDNA (King and Attardi, 1989). EtBr intercalates between the 
bases of the DNA and hence inhibits the replication leading to depletion of the 
nuclear and mitochondrial DNA. However, it is well-known that EtBr shows several 
undesirable side effects like the inhibition of transcription and translation as well as 
the generation of mutations (Hayashi et al., 1990; Maniura-Weber et al., 2004; 
Tønnesen and Friesen, 1973; Zylber et al., 1969). EtBr is assumed to selectively 
inhibit the transcription of the circular mtDNA by altering the tertiary structure, e.g. by 
introducing twists (Zylber et al., 1969). The effect of EtBr on the protein synthesis 
results both indirectly from a decay of the mRNA pool and directly from a decay of 
the protein synthesizing capacity (Tønnesen and Friesen, 1973). 
 
Another possibility to decrease the mtDNA copy number is using 2’, 3’-
dideoxycytidine (ddC). This substance is a prominent antiviral analog of 
deoxycytidine, lacking the 3’-oxygen additionally to the 2’-oxygen of the ribose moiety 
and serving as a substitute substrate for the virally encoded reverse transcriptase 
(Brown and Clayton, 2002; Chen and Cheng, 1989; Martin et al., 1994; Pan-Zhou et 
al., 2000; Piechota et al., 2006a; Reardon, 1992; Waqar et al., 1984; Zimmermann et 
al., 1980). It competes with the natural substrate deoxycytidin for incorporation into 
the DNA (Waqar et al., 1984). The replication is terminated due to the missing 3’-
oxygen of ddC leading to cessation of strand elongation (Mitsuya et al., 1987; 
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Starnes and Cheng, 1987). The substance ddC has been shown to possess a 
negligible low cytotoxicity (Mitsuya et al., 1987; Starnes and Cheng, 1987; Waqar et 
al., 1984). This low cytotoxicity can be explained by the high resistance of 
polymerase α, the major enzyme involved in nuclear DNA replication, which is 
presumably related to its high substrate specifity (van der Vliet and Kwant, 1981), 
whereas polymerase γ (POLG) can use ddC as substrate (Lee et al., 2009; Waqar et 
al., 1984). This indicates that the mitochondrially located POLG is a likely target for 
inhibition of replication by ddC (Lee et al., 2009). In contrast to EtBr with its manifold 
effects, the substance ddC is assumed to preferably inhibit the DNA replication within 
the mitochondria with minimal other cytotoxic side effects.  
 
To test the effects of mtDNA depletion on the bioenergetic activity of the cells, an in 
vitro system with fibroblasts was utilized, since the availability of different human 
tissues was limited. Firstly, we depleted the mtDNA using EtBr or ddC. To minimize 
the risk of artifacts, which could be generated by toxic side effects, we compared the 
effects of the two substances, which act by different mechanisms.  
The concentration of 20 µM ddC was chosen according to Brown and Clayton (2002) 
and Piechota et al. (2006a), which successfully depleted murine LA9 and HeLa cells 
down to 20 % and 4 % mtDNA, respectively. The concentration of 0.13 µM EtBr was 
likewise based on literature reports (Diaz et al., 2002; Piechota et al., 2006a; Trounce 
et al., 1994). We observed in our experiments with fibroblasts treated for 25 days 
with ddC or EtBr in vitro a strong decrease in their mtDNA copy number down to 0.31 
% or 5.65 %, respectively (figure 18A; figure 18B). The efficiency of the mtDNA 
depletion is certainly dependent on the used cell type and the applied concentration 
of the depletive reagent. In one study, where the hepatic tumor cell line HepG2 was 
exposed to a concentration of 0.5 µM ddC for five days, a reduction of the mtDNA 
content to about 8 % of untreated cells was observed, and moreover a concentration 
of 5 µM ddC even led to cell death (Martin et al., 1994). On the other hand, a 20 µM 
ddC concentration applied on mouse fibroblast LA9 cells for five days resulted in a 
weaker depletion to about 20 % of control cells (Brown and Clayton, 2002). This 
difference is possibly due to different cell lines. 
 
The citrate synthase (CS) activity was measured additionally in order to discriminate 
the effects of mtDNA depletion from potential changes in the amount of mitochondria 
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(figure 19). The CS activity is generally used as indicator for the mitochondrial 
amount (Figueiredo et al., 2008; Sarnat and Marín-García, 2005). The CS activity did 
not significantly change during the depletion treatment. This stability in the time 
course of depletion treatment is consistent with the data reported by Pan-Zhou et al. 
(2000). 
Based on the stability of the CS activity, it can be concluded that the mitochondrial 
mass stayed relatively stable within the cells, so that only the number of mtDNA 
molecules per mitochondrion decreased. One can suggest that defects detected 
during the depletion experiment are related to mtDNA depletion, whereas an 
influence of mitochondrial mass changes can be excluded. 
 
To assess the bioenergetic activity of the cells, a measurement of respiration rates 
using complex I- and complex II-dependent substrates was performed.  
The complex I-dependent respiratory activity was determined by application of the 
substrates pyruvate and malate. Glutamate, a further complex I-dependent substrate, 
was added to exclude a direct influence of pyruvate dehydrogenase on the 
respiratory activity. In case of a potential pyruvate dehydrogenase (PDH) complex 
defect, a ‘short variant’ of citric acid cycle can take place, since glutamate is imported 
into the mitochondrial matrix by the glutamate/aspartate exchanger. In this ‘short 
variant’ of citric acid cycle, malate is metabolized until oxaloacetate is generated. 
Then the glutamate oxaloacetate transaminase converts glutamate and oxaloacetate 
to aspartate and α-ketoglutarate. Bypassing PDH with glutamate resulted in no 
significant changes in our experiments. 
The complex II-dependent respiratory activity was measured by application of the 
substrate succinate and the complex I inhibitor rotenone. 
 
The mtDNA depletion caused by ddC- and EtBr-treatment led to a strong decrease of 
the respiratory activity of the cells. It can consequently be argued that the mtDNA 
content influences the bioenergetic state of the cell. 
The inhibition of the respiratory activity was stronger visible in the measurements of 
the complex I-dependent than of the complex II-dependent respiration. This can be 
explained by the additional involvement of complex II, who contains seven 
mitochondrially encoded subunits.  
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The reduction of the respiratory activity proceeded initially faster in EtBr-treated cells 
possibly due to toxic side effects of EtBr. During the later course of the experiment, 
the impairment of the respiration reached similar values in EtBr- and ddC-treated 
cells. The reduction impaired not only the basic cell respiration, but to a large extend 
respiration under stimulated conditions e.g. after ADP-addition or TTFB-uncoupling. 
This means that the depletion has, beside effects on the basic metabolism of cells, 
additionally strong consequences on the handling of metabolic short-term loads. 
Patients affected by mitochondrial disorders often suffer from a severe impairment of 
muscle and brain activity. These tissues are strongly dependent on a short-term 
energy supply. Therefore, an energy deficit due to depletion would have a high 
impact preferably on tissues with an elevated energy demand. 
 
The reduction of the mtDNA copy number and the decrease of the respiratory activity 
in EtBr-treated fibroblasts were found to be correlated in a linear way (figure 27). By 
contrast, the relationship between mtDNA copy number and respiration in ddC-
treated fibroblasts possesses a logarithmic dynamics with a potential threshold 
(figure 26). Various factors could cause the difference between the experimental 
results of ddC- and EtBr-depleted cells. The linear correlation in EtBr-treated cells 
could result from toxic side effects of EtBr like an impairment of transcription and 
translation (Hayashi et al., 1990; Maniura-Weber et al., 2004; Tønnesen and Friesen, 
1973; Zylber et al., 1969). The amount of required mitochondrial proteins involved in 
the respiratory chain would not only be reduced by a lower mtDNA copy number, but 
also by a diminished synthesis of mitochondrial encoded mRNAs and proteins. The 
decreased amount of mitochondrial encoded subunits of the respiratory chain would 
impair the ability of the cells to maintain their bioenergetic properties even at higher 
mtDNA copy numbers.  
 
The mtDNA content and the respiratory activity in ddC-treated cells are correlated by 
a threshold-like dependency. Before reaching a certain limit, the mtDNA copy 
number has no strong influence on the respiratory activity and the cell possesses a 
relatively normal metabolism. However, as soon as the mtDNA content falls under 
this limit, the bioenergetic activity decreases rapidly. This suggests that the mtDNA 
content potentially features a certain threshold, which could represent the limit for the 
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ability of the cells to maintain with the residual mtDNA amount an almost constant, 
regular bioenergetic status.  
 
It can be assumed that the mtDNA molecules could possibly exist in a surplus within 
the cell. This surplus of mtDNA molecules could have a protective effect against 
deleterious mutations. A certain reserve amount of wildtype mtDNA molecules in 
heteroplasmic cells ensures the energy production within the cell. Strictly speaking, 
the cell could than tolerate a certain loss of wildtype mtDNA without major problems. 
 
The threshold was calculated as the mtDNA content at half maximal respiratory 
activity. For the complex I- and the complex II-dependent respiration, a threshold of 
about 24 (4 %) and seven (1 %) mtDNA copies per nucleus was determined, 
respectively (figure 26), which indicates a considerable excess of mtDNA in human 
fibroblasts. 
An amount between two and ten mtDNA molecules per mitochondrion is quoted in 
several literature reports (Graziewicz et al., 2006; Shuster et al., 1988; Wiesner et al., 
1992). According to this generally accepted ratio between mtDNA copies and 
mitochondria within cells, the mtDNA content of 563 mtDNA molecules detected in 
the applied fibroblast cell line would correspond theoretically to 56-282 mitochondria 
per cell.  
 
The calculated mtDNA copy number threshold lies with 24 (4 %) and seven (1 %) 
mtDNA copies per nucleus somewhat below the minimal amount of one mtDNA 
molecule per mitochondrion. Considering that the mtDNA molecules are clustered in 
protein-DNA-structures called nucleoids (Chen and Butow, 2005, Wang and 
Bogenhagen, 2006), it is most likely that the calculated threshold value is 
consequently also below the minimal amount of one mtDNA molecule per nucleoid.  
However, since we correlated the respiratory activity of cells to a permanently 
decreasing mtDNA copy number, a delayed impairment of the respiration due to a 
residual activity of proteins with a long half-life cannot be excluded. For this reason, it 
is conceivable that the bioenergetic activity could be lower in cells in vivo with a 
stably depleted mtDNA content.  
This potential discrepancy could be explained by intermitochondrial exchange 
processes, which would attenuate the bioenergetic problems. Since it is assumed 
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that mitochondria exist in a dynamic network within the cell (Frazier et al., 2006; 
Rizzuto et al., 1998), an exchange of mRNA, tRNAs or even missing subunits of the 
OXPHOS within the mitochondria could alleviate the effects of depletion.  
 
Addressing the aspect, whether accumulating mutant mtDNA molecules or missing 
wildtype mtDNA molecules are more relevant for the phenotype of mitochondrial 
disorders, we provided evidence that a small amount of wildtype mtDNA molecules in 
the cell could sustain the biochemical functionality of the cell. It is controversially 
discussed if the onset and severity of mitochondrial disorders with mtDNA 
heteroplasmy, i.e. a mixture of wildtype and mutated mtDNA molecules within the 
cells, results from the presence of mutated molecules (Shoubridge et al., 1990), from 
the absence of wildtype molecules (Attardi et al., 1995) or from a mixture of both 
(Attardi et al., 1995; Bentlage and Attardi, 1996). A couple of mitochondrial disorders 
exist, where identical mutations with a different level of mutated mtDNA molecules 
lead to different symptoms. Prominent examples are the disorders maternally-
inherited Leigh syndrome (MILS) and neuropathy, ataxia and retinitis pigmentosa 
(NARP) (Alexeyev et al., 2008; Mäkelä-Bengs et al., 1995) The mtDNA mutation 
T8993G is present at a level of 60-90 % and at a level of more than 90 % in patients 
affected by NARP and MILS, respectively (Alexeyev et al., 2008; Mäkelä-Bengs et 
al., 1995). 
 
A sharp threshold was similarly observed in one study, where heteroplasmic mixtures 
of mtDNA wildtype and mutant molecules were generated in an in vitro system 
(Chomyn et al., 1992). The mutant molecules carried the A8344G mutation, which is 
associated with the disorder myoclonic epilepsy and ragged red fibers (MERRF) 
(Chomyn et al., 1992). A correlation between the oxygen consumption and the 
mutation load of the transformants revealed a threshold at a wildtype mtDNA content 
of approximately 6 % (Chomyn et al., 1992).  They concluded that a small minority of 
wildtype molecules could protect the transformants against the defect caused by the 
mutation (Chomyn et al., 1992). One interpretation of these findings was that the 
products of the wildtype and the mutant mtDNA molecules could interact leading to a 
complementation of the defect caused by the mutation (Attardi et al., 1995). 
However, our experiment, which was performed without potentially interfering mutant 
mtDNA molecules, supports the interpretation that the wildtype molecules are 
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themselves sufficient to provide the cells with normal respiratory activity (Attardi et 
al., 1995). This finding extends the knowledge on the relationship between the 
mtDNA content and bioenergetic problems, which improves the assessment of the 
phenotype of several diseases. 
 
However, several factors could lead to an underestimation of the mtDNA threshold 
detected for ddC-treated cells. The decrease of the respiratory activity could be 
delayed due to a relatively long half-life of residual RNA and proteins.   
A time-shift of the respiration decrease due to transcript stability is negligible since 
mitochondrial transcripts in HeLa cells are assumed to generally possess a relatively 
short half-life between one and seven hours (Piechota et al., 2006b). However, a 
delayed decrease of the respiration due to residual proteins cannot be excluded. It 
has been reported that the turnover rate of mitochondrial proteins from rat liver lasts 
several days (Swick et al., 1968). A delayed decrease of the protein content could 
influence the kinetics during the experiment. This could potentially alter the 
relationship between the mtDNA content and the bioenergetic status of the cell, 
leading to the detected “too low” threshold.  
 
The processes, which influence the size of this potential threshold, remain to be 
elucidated. Very likely, the critical amount of mtDNA copies is influenced by the 
content and distribution of the mitochondria within the cells.  
 
6.2 Importance of the mtDNA content on neurodegeneration 
It was intended to take a closer look at the importance of the mtDNA maintenance on 
the mitochondrial functionality with a possible view on the clinical phenotype of 
patients with a mitochondrial disease. For this reason, the mtDNA content should be 
correlated to the clinical phenotype found in patients with Ammon’s horn sclerosis 
(AHS), a prominent pathological finding of temporal lobe epilepsy (TLE) (Liu et al., 
1995; Sommer, 1880).  
 
In TLE with AHS, neurodegenerative mechanisms are associated with extensive 
seizures, which take place in the hippocampal region (Chang and Lowenstein, 2003). 
It has been reported that seizures can lead to necrotic and apoptotic cell death 
processes in neurons (Bengzon et al., 1997). However, the cause and effect 
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relationship between seizures and the apoptosis of specific cell types still remains to 
be elucidated (Chang and Lowenstein, 2003; Kunz, 2002). It is controversially 
discussed, whether the hippocampal sclerosis in TLE with AHS is a consequence of 
prolonged seizures, or whether it contributes to the development of the epileptic 
focus (Berkovic and Jackson, 2000; Jefferys, 1999). Studies revealed that an 
experimental focal status epilepticus resulted in histological changes resembling 
human hippocampal sclerosis (Sloviter, 1994). On the contrary, seizures with only a 
low incidence of neuronal cell loss or hippocampal sclerosis are likewise reported 
(Jefferys et al., 1992). It has been hypothesized that even if hippocampal sclerosis 
may not be essential for epilepsy, it could still promote its development (Jefferys, 
1999). This raises the question, how the decreased mitochondrial activity is 
correlated with the pathogenic changes in neuronal cells within specific brain regions. 
 
To address the issue of mtDNA copy number changes during neurodegenerative 
processes within the brain, a comparison of the hippocampal regions of TLE patients 
with AHS and control patients was performed. The control patients were only affected 
by lesional damage of the brain tissue close to the hippocampus (e.g. 
parahippocampal tumor), which is not related to the sclerotic processes observed in 
AHS patients. Since the loss of pyramidal neurons in the areas cornu ammonis 1 
(CA1) and cornu ammonis 3 (CA3) in the hippocampus is a histopathological 
hallmark of AHS (Baron et al., 2007; Ben-Ari et al., 1980; Kunz et al., 2000; Liu et al., 
1994; Liu et al., 1995; Nadler, 1981), these areas were of special interest.  
 
The mtDNA copy number was found to be significantly decreased in AHS patients in 
the hippocampal regions CA1 to 47 % and CA3 to 56 % compared to the respective 
regions from lesion patients, whereas no significant mtDNA depletion was detected in 
the neighboring tissue regions area dentata (AD) and parahippocampus (PH) (figure 
17; table 22; paragraph 5.6; Baron et al., 2007). A depletion of mtDNA in the regions 
CA1 and CA3 was also detected in the hippocampus of pilocarpin-treated epileptic 
rats underlining the observed phenomenon (Kudin et al., 2002). Furthermore, both a 
mitochondrial dysfunction, marked by an impairment of the respiratory chain 
complexes (Kudin et al., 2002; Kunz et al., 2000), and a decrease of the 
mitochondrial density, indicated by a decrease of the CS activity (Baron et al., 2007), 
have been reported for the affected areas CA1 and CA3.  
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The decrease of mtDNA copy number, mitochondrial content and mitochondrial 
functionality in specific neuronal areas hints to cell-type specific changes in these 
areas. The detected mtDNA depletion in the hippocampal regions CA1 and CA3 in 
TLE patients with AHS can be an indication of a loss of pyramidal neurons induced 
by epileptic seizures. Since the mtDNA depletion was specifically reduced in the 
hippocampal regions CA1 and CA3, which are associated with a decreased 
mitochondrial number and function as well as the loss of pyramidal neurons, one can 
assume an intimate relationship between a decrease in the mtDNA copy number and 
neuronal damages that characterize AHS.  
 
In this selective neurodegenerative process in the hippocampus, which finally leads 
to sclerosis of brain tissue, mitochondria are both targets of oxidative damage and 
sources of reactive oxygen species (ROS). A dysfunction of mitochondrial electron 
transport proteins leads to the production of ROS (Han et al., 2001; Kudin et al., 
2004). In addition to the formation of 8-hydroxyguanosine (8-OHG) (Halliwell and 
Aruoma, 1991; Richter et al., 1988), the hydroxyl radical •OH can react with 
deoxyribose, which leads to sugar radicals. ROS can induce single and double 
strand breaks in the mtDNA, which can induce active degradation of the mtDNA (Lee 
and Wei, 2005; Richter et al., 1988; Shibutani et al., 1991; Shokolenko et al., 2009). 
For this reason, a causative relationship between an increased ROS production and 
a decreased mtDNA copy number is plausible. 
 
Since the mitochondrial content of cell types varies regionally within the brain, the 
regional selectivity of neurodegenerative processes can be explained. Certain brain 
areas seem to be preferentially affected by mtDNA changes. The reasons for this 
selectivity have not been elucidated yet. Different neuronal cell types might be 
dependent to a different degree on the energy supply by mitochondria. Their 
functionality can be impaired due to mtDNA depletion, deletion or point mutations. 
Thus critical factors, which could determine the survival of the particular neuronal 
cells are the degree of mtDNA damage as well as their intrinsic threshold (Baron et 
al., 2007). These factors influence different neuronal cells to a different degree 
according to their mitochondrial content. This might explain at least in part the cell 
type specifity of this process. 
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6.3 Influence of the nuclear gene POLG on the mtDNA copy number 
There are several primary POLG mutations known to cause secondary defects in the 
mtDNA, for example point mutations or deletions, which can lead to various 
mitochondrial diseases like progressive external ophthalmoplegia (PEO) or Alpers-
Huttenlocher syndrome (Chan and Copeland, 2009). The relationship between the 
location of mutated amino acids encoded by POLG and their specific functional 
consequences remains to be elucidated.  
 
It is assumed that a defect in the proof reading ability of polymerase γ leads to the 
accumulation of mutations within the mtDNA, whereas an inhibited polymerase 
activity causes a reduction of the mtDNA copy number (Spelbrink et al., 2000). The 
most frequent pathogenic POLG mutations are located in the so-called linker region 
(Chan and Copeland, 2009; Kaguni, 2004; Luoma et al., 2005; Van Goethem et al., 
2001). This region is proposed to fulfil multiple functions, whereby mutations located 
in this region lead to various biochemical effects (Lee et al., 2009). The correlation 
between pathogenic mutations in the linker region and the occurrence of the disease 
phenotype could thus be based on an impaired enzyme catalysis, a decreased DNA 
binding affinity, or a reduced interaction of the catalytic and the accessory 
polymerase γ subunits (Lee et al., 2009).    
 
Since the mutation A467T probably occurs in 36 % of all alleles in POLG disease 
populations, it is regarded as the most widespread pathogenic mutation in POLG 
(Chan and Copeland, 2009). It has been reported that a recombinant polymerase γ 
catalytic subunit, containing the A467T mutation in the linker region, exhibits both a 
lowered binding capability to the accessory subunit and a severe DNA binding defect 
(Chan et al., 2005). These observations were accompanied by a lowered polymerase 
and exonuclease activity (Chan et al., 2005). The mutation W748S and the 
polymorphism E1143G are often found together in cis on the same allele (Chan et 
al., 2006; Hakonen et al., 2005; Nguyen et al., 2005; Nguyen et al., 2006; Tzoulis et 
al., 2006; Van Goethem et al., 2004). A recombinant polymerase γ catalytic subunit 
with the W748S mutation possessed low DNA polymerase activity, low processivity 
and a reduced DNA binding capability (Chan et al., 2006).  
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The Alpers-Huttenlocher syndrome is a mitochondrial disease, which is associated 
with mutations in POLG. It is known as a typical mtDNA depletion disorder (Naviaux 
et al., 1999), whereas only few reports on mtDNA point mutations (Zsurka et al., 
2008) or deletions (Ashley et al., 2008; Zsurka et al., 2008) exist. For this reason, the 
tissues of Alpers-Huttenlocher patients were examined for mutations in the POLG 
gene. In five pediatric patients, a total of four pathogenic mutations A467T, W748S, 
F749S and L752P in the linker region as well as the mutation G848S and the 
polymorphism E1143G in the polymerase domain were identified (paragraph 5.5; 
Zsurka et al., 2008). The mutations A467T, W748S, F749S and G848S are well-
known deleterious POLG mutations associated with mitochondrial disease (Chan et 
al., 2005; Davidzon et al., 2005; Hakonen et al., 2005; Nguyen et al., 2006; Van 
Goethem et al., 2004; Zsurka et al., 2008). The newly identified mutation L752P 
occurred in one patient in compound heterozygous way (Zsurka et al., 2008).  
 
In all examined tissues of the patients with Alpers-Huttenlocher syndrome, a mtDNA 
depletion was detected (table 20). The severity of this depletion ranged from a mild 
decrease to 75 % mtDNA to a severe reduction to 11 % mtDNA of the control values 
in hippocampal brain and liver, respectively. The determined mtDNA depletion values 
are supported by literature data, where a reduction to 25 % mtDNA (Naviaux et al., 
1999) and 13 % mtDNA (Ashley et al., 2008) of control specimen in liver has been 
detected. In muscle specimen, a comparable reduction to 30 % mtDNA (Naviaux et 
al., 1999) and 55 % mtDNA (Ashley et al., 2008) has been reported. 
In contrast, an analysis for mtDNA deletion revealed only a very small amount of 
deleted mtDNA molecules of less than 1 % in each tissue (Zsurka et al., 2008). If one 
compares the strength of the effect of the mtDNA deletion and the mtDNA reduction, 
the crucial factor related to bioenergetic problems in patients suffering from Alpers-
Huttenlocher syndrome seems to be the mtDNA depletion. The detected depletion 
indicates a correlation of specific POLG mutations and the mtDNA copy number 
phenotype.  
 
We assumed a relation between the valproate-induced liver failure and the severe 
mtDNA depletion in liver tissue of patient one (p1) (table 19; table 20; Zsurka et al., 
2008). Histochemically, liver regions with different cytochrome c oxidase (COX) 
activity were observed (figure 15; Zsurka et al., 2008) indicating regions with intact 
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and defect mitochondria. A variation of the mitochondria content and morphology in 
neighboring hepatocytes from patients with Alpers-Huttenlocher syndrome has 
already been reported (Naviaux et al., 1999). The mitochondrial morphology ranges 
from mitochondria with tightly packed cristae or concentric cristae to normal 
appearing mitochondria (Naviaux et al., 1999).  
We correlated the histochemical findings, showing defects of the OXPHOS, with the 
mtDNA copy number. Liver regions with different COX staining were microdissected 
to determine the OXPHOS activity and the mtDNA content. The COX-negative areas 
contained indeed about fourfold less mtDNA (6 % from control) than the COX-
positive areas (26 % from control) (figure 16; table 21). These findings hint to a 
correlation between the mitochondrial functionality and the mtDNA copy number. 
They are in accordance with Ashley et al. (2008), who observed a corresponding 
pattern of depletion and COX deficiency in cultured fibroblast cells of Alpers-
Huttenlocher patients.  
In contrast to the strong depletion, only a very low amount of 0.02 % deleted mtDNA 
molecules was detected in liver (Zsurka et al., 2008). The negligible small amount of 
deleted molecules suggests an only marginal contribution of the deletion to the 
disease phenotype although a specific impairment of single cells with an impact on 
larger tissue areas cannot be excluded. 
 
Additionally to the patients with the severe Alpers-Huttenlocher syndrome, a mild 
phenotype of PEO with epilepsy/ataxia was surprisingly detected in a family carrying 
the POLG mutations A467T and W748S (figure 12; paragraph 5.4; Paus et al, 2008). 
The family members carrying either heterozygously the mutation W748S or A467T 
showed no disease phenotype. However, the two daughters with both compound 
heterozygous mutations were affected by a number of neurological symptoms like 
epilepsy, ataxia, neuropathy and a mild phenotype of PEO. Additionally, they 
exhibited a significantly reduced mtDNA copy number in blood samples (figure 13; 
table 18).  
It is therefore most likely that the combination of the pathogenic POLG mutations 
W748S and A467T could have an influence on the mtDNA copy number as well as 
on the pathogenic phenotype of the disease. In addition, a DNA mutation analysis 
was performed. Indeed, also multiple deletions were detected in muscle tissue 
specimen of both affected daughters (Paus et al., 2008). Therefore, an additional 
Discussion                                                                                                                                    82
influence of the deleted molecules found in the patients with the PEO phenotype 
cannot be excluded. 
 
Disregarding the relevance of deletions, one can assume that the pathogenic factor 
in patients with the investigated pathogenic POLG mutations causing a mitochondrial 
disease phenotype, is mtDNA depletion. The impaired polymerase activity caused by 
primary POLG mutations can cause the reduction of the mtDNA copy number. 
Additionally, secondary mtDNA point mutations and deletions can be generated 
either by lowered rate of mutation repair or higher rate of mutagenesis of single 
stranded replication intermediates resulting from abnormal replication stalling 
(Wanrooij et al., 2007). The accumulation of these mutated molecules can moreover 
be enhanced by a decreased total amount of mtDNA molecules since the 
segregation speed is higher when less segregating units are present (Coller et al., 
2002; Preiss et al., 1995). This would consequently lead to a stronger segregational 
drift to mutated mtDNA molecules. 
 
6.4 Tissue-specifity of the mtDNA content 
A mitochondrial dysfunction mainly occurs in tissues, which are highly dependent on 
energy supply and consequently on their mitochondria. The functionality of the 
OXPHOS depends, amongst others, on a correct transcription and translation of the 
mtDNA. 
Since literature data on the tissue-specifity of the mtDNA content are ambiguous, we 
focused our interest on the mtDNA copy number in several tissues and cell types.  
We were also interested in the correlation between the mtDNA copy number and the 
mitochondria content in various tissues.  
 
Firstly, we determined the mtDNA content in several tissues and cell types of human 
controls (figure 11; table 16; paragraph 5.2). The samples were taken from skeletal 
muscle, brain specimen, liver, buccal mucosa, fibroblasts and blood. The highest 
mtDNA copy number values were detected in tissue specimen of skeletal muscle and 
brain with 16,864 ± 8,843 and 7,145 ± 4,086 mtDNA copies, respectively. A high 
mtDNA copy number is in line with a high energy requirement since the energy 
support via mitochondria is especially needed in brain and muscle tissue. The brain 
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is metabolically a very active organ with a high constant demand for oxygen, i.e. 20 
% of the resting total body consumption (Clarke and Sokoloff, 1999). Muscle fibers 
generally perform a large scale of mechanical work and require energy dependent on 
their physiological activity.  
 
Other tissues and cell types with a lower energy demand possessed a lower mtDNA 
copy number with the lowest value of 283 ± 99 mtDNA copies detected in our blood 
DNA isolates. This value is in accordance with literature data like 240-420 mtDNA 
copies in lymphocytes (Szuhai et al., 2001) and ~ 250-500 mtDNA copies in 
leukocytes (Pyle et al., 2007). These data for lymphocytes and leukocytes were 
likewise quantified with quantitative PCR (qPCR) (Pyle et al., 2007; Szuhai et al., 
2001). In one literature study, a value of ~ 800 mtDNA copies in lung fibroblasts has 
been quantified with Southern blot (Robin and Wong, 1988). This value is 
comparable with our data of 961 ± 242 mtDNA copies in cultured fibroblasts, even 
though different techniques for mtDNA quantification were applied. 
 
In addition to normal human tissues and cell types, we investigated the epithelial 
cancer HeLa cell line. In comparison to epithelia with low energy demand like 
fibroblasts, the HeLa cells showed a relatively high value of 1,161 ± 228 mtDNA 
copies. This value is similar to the mtDNA copy number determined by others. The 
reported data for the mtDNA content in HeLa cells are in a range between 1000 
(Takamatsu et al., 2002) and 9100 mtDNA copies (King and Attardi, 1989). A high 
mtDNA content in cervical HeLa cells is in accordance with the upregulation of the 
mtDNA content reported for a number of human malignancies (Jones et al., 2001; 
Simonnet et al., 2002; Wang et al., 2006; Wong et al., 2004). Possible reasons for 
the mtDNA copy number increase in cancer cells could be either directed metabolic 
adaptions or undirected defective regulations. However, the issue of mtDNA copy 
number variations in tumorous cells is very complex. For instance, also contradictory 
reports pointing to a downregulation of the mtDNA copy number in tumorous cells 
exist (Lee et al., 2004; Wong et al., 2004).  
 
Several mtDNA copy number data for some species and different tissues are 
available in the recent literature. However, mainly data of singular tissues or cell 
types exist, but systematic studies on mtDNA copy number values in several human 
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tissues are still missing. Our determined values, which are in agreement with 
literature data, suggest a tissue dependent variation of the mtDNA copy number.  
 
The current opinions in the literature state a proportion of two to ten mtDNA 
molecules per mitochondrion (Graziewicz et al., 2006; Shuster et al., 1988; Wiesner 
et al., 1992). The mitochondria content varies strongly in a tissue- and celltype-
specific range of about 100,000 mitochondria per oocyte (Ankel-Simons and 
Cummins, 1996; Chen et al., 1995) to four mitochondria per platelet (Shuster et al., 
1988). We intended to examine in depth the general assumption of a stable ratio of 
the mtDNA copy number among mitochondria. In this context, we decided to 
determine the mitochondria content on the basis of the CS activity and to correlate 
these CS activity values to the mtDNA copy number afterwards (table 17; paragraph 
5.3). Here, the CS activity presumably indicates the mitochondrial mass (Figueiredo 
et al., 2008; Sarnat and Marín-García, 2005).  
 
In hippocampal brain and skeletal muscle, the determined CS activity exhibited high 
values of 195 ± 30 µmol/(g⋅min) and 166 ± 36 µmol/(g⋅min), respectively. The high 
CS activity values are an indicator for a high mitochondria content. This is in 
accordance with the high energy demand of these tissues. Several similar data can 
be found in literature with values for muscle between 113 and 232 µmol/(g⋅min) 
(Barthélémy et al., 2001; Gellerich et al., 2002; Sarnat and Marín-García, 2005; Van 
den Bogert et al., 1993). In brain specimen, CS activity values between 89 and 375 
µmol/(g⋅min) have been mentioned (Bowling et al., 1993; Van den Bogert et al., 
1993). Cell types with a lower energy demand contained a lower CS activity. For 
instance, a low CS activity of 68 ± 7 µmol/(g⋅min) in fibroblasts and 32 ± 10 
µmol/(g⋅min) in buccal mucosa was detected. Similar data for fibroblasts with 62 
µmol/(g⋅min) and HeLa cells with 136 µmol/(g⋅min) can be found in literature (Van 
den Bogert et al., 1993). The lower CS activity indicates a smaller total volume of 
mitochondria in the cells, which can be due both to a smaller volume of individual 
mitochondria or a smaller total number of mitochondria in the cells. It can be 
concluded that the mitochondrial mass corresponds to the energy demand of the 
respective tissue. 
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The CS activity of the tumorous HeLa wildtype cell line is in the range of the other 
measured values. Surprisingly, Hela ρ0 cells containing mitochondria depleted of their 
mtDNA exhibited a CS activity, which was raised about 44 % compared to HeLa 
wildtype cells. It could be possible that the HeLa ρ0 cells increase their mitochondrial 
mass as an attempt to compensate the missing mtDNA. 
 
Furthermore, the mtDNA copy number was correlated to the CS activity, which 
resulted in a ratio between 14 and 35 in the majority of examined cell types. One 
value, which differed from the other measured data was the ratio of 109 related to 
skeletal muscle specimen. The origin of this unexpected value is not clear, but could 
originate from different causes.  
Firstly, it could be possible that the unexpected high ratio between mtDNA copy 
number and mitochondria content in muscle fibers might result from a high mtDNA 
accumulation. This could be correlated to tissue specific tasks of these organelles in 
skeletal muscle fibers. Each of the skeletal muscle fibers is a syncytium containing 
several nuclei in a combined cytoplasma, which is generated by the fusion of 
myoblasts during muscle development (Horsley and Pavlath, 2004; Jansen and 
Pavlath, 2008). 
Secondly, a tissue specific variation of the CS expression cannot be excluded. CS is 
an accepted marker for the mitochondrial volume (Figueiredo et al., 2008; Sarnat and 
Marín-García, 2005), although a variation of the CS activity in several tissues has 
been reported (Kirby et al., 2007). However, in comparison to other metabolic 
enzymes like the respiratory chain complexes, the changes of the CS activity are 
lower, justifying the usage of the CS activity as an indicator for the abundance of 
mitochondria (Kirby et al., 2007). 
 
From our experiments, we concluded that the mitochondria content is generally 
proportionate to the mtDNA content in most healthy human tissues. This confirms 
earlier reports of the proportionality of the mtDNA content and the mitochondrial 
volume (Moyes et al., 1997; Puntschart et al., 1995). However, muscle seems to be 
an exception possibly due to its special requirements for mitochondrial tasks.  
Even though the ratio between mtDNA copy number and mitochondria content in 
muscle seems to be exceptionally high, it has been reported that the principle of a 
stable relation between mtDNA content and oxidative capacity maintained within this 
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tissue (Wang et al., 1999; Williams, 1986). More precisely, a relation of mtDNA 
content and oxidative capacity was not only reported in differing types of muscle 
fibers, but it also persisted during metabolic alterations due to exercise and chronic 
stimulation of skeletal muscle (Wang et al., 1999; Williams, 1986). 
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7. Summary 
The aim of this thesis was to investigate the relevance of the mitochondrial DNA 
(mtDNA) depletion, i.e. copy number reduction, as potential cause of mitochondrial 
disorders. The combined occurrence of mtDNA depletion and several clinical 
syndromes of mitochondrial diseases has been reported in the literature (Clay 
Montier et al., 2009; Durham et al., 2005). However, the causative relationship 
between mtDNA copy number and the clinical phenotype is not elucidated yet. The 
analysis of the mtDNA depletion was performed with quantitative PCR (qPCR) on 
tissue specimen of patients affected by a mild phenotype of progressive external 
ophthalmoplegia (PEO) with epilepsy/ataxia, Alpers-Huttenlocher syndrome, and 
temporal lobe epilepsy (TLE) with Ammon’s horn sclerosis (AHS). 
 
A reduction of the mtDNA copy number was likewise determined in several tissues 
and cell types of Alpers-Huttenlocher patients with POLG (polymerase γ) mutations. 
Only a small amount of deleted mtDNA molecules was present in tissues of Alpers-
Huttenlocher patients, which suggests a negligible impact of deleted molecules to the 
disease phenotype, whereas the mtDNA copy number reduction strongly correlates 
with the biochemical phenotype. However, an influence of deleted molecules 
detected in patients affected by a mild phenotype of PEO with epilepsy/ataxia cannot 
fully be excluded. 
 
A pattern of liver areas with decreased cytochrome c oxidase (COX) activity and a 
corresponding pattern of mtDNA copy number reduction were observed in one 
Alpers-Huttenlocher patient. Since these patterns overlap, it can be suggested that a 
reduction of the mtDNA content potentially limits the metabolic activity of cells. The 
comparison of muscle specimen from an Alpers-Huttenlocher patient at an early and 
a later biopsy time point revealed that the mtDNA copy number was more severely 
reduced in the sample biopsied at a later life-time. This finding hints to a progressive 
decline of the mtDNA copy number in the affected tissues.  
 
A relation of mtDNA depletion to the energy requirement of cell types and tissues 
could be confirmed. A high mtDNA copy number was measured in tissues with a high 
energy demand like muscle or brain, whereas accordingly a low mtDNA copy number 
Summary 88
was detected in low energy demand tissues and cell types like blood. This tissue 
specific mtDNA content further correlated with the mitochondrial mass. 
 
In different hippocampal regions of patients affected by AHS, a depletion of the 
mtDNA was detected. These specific hippocampal regions cornu ammonis 1 (CA1) 
and cornu ammonis 3 (CA3) with mtDNA depletion are additionally affected by a 
decreased mitochondrial mass (Baron et al., 2007) and mitochondrial functionality 
(Kudin et al., 2002; Kunz et al., 2000) as well as a neuronal cell loss. Since an 
increased level of reactive oxygen species (ROS) was reported for several 
neurodegenerative diseases as a hallmark of mitochondrial impairment, it can be 
suggested that a ROS induced mtDNA depletion might result in a decreased 
expression of mtDNA encoded enzymes of respiratory chain complexes and 
consequently to an energy deficit in the cell and finally to cell death. A correlation 
between the mtDNA copy number reduction and the neuronal impairment can be 
assumed.  
 
Using an in vitro assay, it was determined that a mtDNA copy number reduction can 
lead to an impaired respiratory metabolism in artificially depleted fibroblasts. The 
biochemical phenotype in cells treated by 2’,3’-dideoxycytidine (ddC) seems to occur 
at a certain threshold level. This threshold indicates that the respiratory activity 
remains stable above a certain mtDNA content, but decreases rapidly below this 
value. The threshold possibly originates from a surplus of mtDNA copies within the 
cell buffering mtDNA mutations or deletions up to a certain level.  
 
One can conclude that a decrease of the mtDNA content affects the expression of 
the mitochondrially encoded enzymes of the oxidative phosphorylation system 
(OXPHOS). A dysfunction of the OXPHOS can result in an energy deficit of the cell. 
The lacking energy can lead to general metabolic problems and even to cell death as 
molecular cause of the clinical phenotype in mitochondrial diseases. 
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8.2 List of abbreviations 
 
acetyl CoA    acetyl coenzyme A 
AD     area dentata 
ADP     Adenosine diphosphate 
adPEO     autosomal dominant PEO 
AHS     Ammon’s horn sclerosis 
ALS     amyotrophic lateral sclerosis 
ANOVA    univariate variance analysis 
ANT1     adenine nucleotide translocator 1 
arPEO     autosomal recessive PEO 
ATP     adenosine-5’-triphosphate 
BLAST     basic local alignment search tool 
Bromophenol blue   3', 3" ,5' ,5"-tetrabromophenolsulfonphthalein 
BS     brain stem 
C     complex 
CA     cornu ammonis 
CA1     cornu ammonis 1 
CA3     cornu ammonis 3 
CB     cerebellum 
DNA     deoxyribonucleic acid 
CoA-SH    coenzyme A 
COX     cytochrome c oxidase 
DAB     3, 3’-diaminobenzidine tetrahydrochloride 
DAPI     4’,6-diamidino-2-phenylindole 
ddC     2’,3’-dideoxycytidine 
dil     dilution factor 
DMEM     Dulbecco’s modified eagle medium 
DMSO     dimethyl sulfoxide 
dNTP     deoxyribonucleotide 
dRP     5’-deoxyribose phosphate 
DTNB     5, 5’-dithiobis-(2-nitrobenzoic acid) 
EDTA     diaminoethanetetraacetic acid 
EtBr 3, 8-diamino-5-ethyl-6-phenylphenanthridinium bromide 
(Ethidiumbromide) 
Exo 3’-5’-exonuclease 
FADH2     flavin adenine dinucleotide 
FAM     6-carboxyfluorescein 
FBS     fetal bovine serum 
FL     frontal lobe 
FRDA     Friedreich’s ataxia 
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GDP     guanosine diphosphate 
GTP     guanosine-5’-triphosphate 
H     hippocampus 
HeLa     Henrietta Lacks 
IMM     inner mitochondrial membrane 
IMS     intermembrane space 
KSS     Kearns-Sayre syndrome 
L     length 
LHON     Leber’s hereditary optic neuropathy 
MELAS mitochondrial encephalomyopathy, lactic acidosis and stroke-
like episodes 
MERRF myoclonic epilepsy and ragged red fibers 
MILS     maternally-inherited Leigh syndrome 
MNGIE mitochondrial neurogastrointestinal encephalomyopathy 
MP morbus Parkinson 
mtDNA     mitochondrial DNA 
MTS     mitochondrial targeting sequence 
NAD+/NADH    nicotinamide adenine dinucleotide 
NADP+/NADPH    nicotinamide adenine dinucleotide phosphate 
NARP     neuropathy, ataxia and retinitis pigmentosa 
NBT     Nitro blue tetrazolium chloride 
NCBI     National Center for Biotechnology Information 
O2-•     superoxide anion 
OD     optical density 
•OH     hydroxyl radical 
8-OHG     8-hydroxyguanosine 
OL     occipital lobe 
OMM     outer mitochondrial membrane 
oxalacetic acid    oxobutanedioic acid 
OXPHOS    oxidative phosphorylation system 
p55     55 kDa protein 
PDH     pyruvate dehydrogenase 
PEO     progressive external ophthalmopegia 
PBS     phosphate buffered saline 
PCR     polymerase chain reaction 
PH     parahippocampus 
PL     parietal lobe 
Pol     DNA-polymerase 
POLG     mtDNA polymerase γ 
RFLP     restriction fragment length polymorphism 
ROS     reactive oxygen species 
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RNA     ribonucleic acid 
rRNA     ribosomal RNA 
RT     room temperature 
qPCR     quantitative real time PCR 
SDH     succinate dehydrogenase 
SDS     sodium dodecyl sulfate 
SE     salt EDTA 
succinyl –CoA    succinyl coenzyme A 
TAE     tris acetate EDTA 
TAMRA    N, N, N’, N’-6-tetramethyl-6-carboxyrhodamine 
Taq     Thermus aquaticus 
TBE     tris borate EDTA 
TE     Tris EDTA 
TFAM     mitochondrial transcription factor A 
TL     temporal lobe 
TLE     temporal lobe epilepsy 
TNB     5-thio-2-nitrobenzoic acid 
Triethanolamine   Tris(2-hydroxyethyl)amine 
Tris     2-Amino-2-hydroxymethyl-propane-1,3-diol 
Triton X-100    Octoxinol-9 
tRNA     transfer RNA 
TTFB     4, 5, 6, 7-Tetrachloro-2-trifluoromethylbenzimidazole 
Tween 20    Polyoxyethylene (20) sorbitan monolaurate 
V     volume 
 
Table 27. Standard amino acid abbreviations 
A Alanine G Glycine M Methionine S Serine 
C Cysteine H Histidine N Asparagine T Threonine 
D Aspartic acid I Isoleucine P Proline V Valine 
E Glutamic acid K Lysine Q Glutamine W Tryptophan 
F Phenylalanine L Leucine R Arginine Y Tyrosine 
 
Appendices 108
8.3 List of figures 
 
Figure 1 .  Citric acid cycle .................................................................................................................... 3 
Figure 2.  Generation of reactive oxygen species (ROS) at the oxidative  
 phosphorylation system (OXPHOS) .................................................................................... 4 
Figure 3.  mtDNA replication mechanisms........................................................................................... 7 
Figure 4.  Structure of the hippocampus ............................................................................................ 14 
Figure 5. Catalytic subunit of POLG.................................................................................................. 15 
Figure 6.  Reaction of acetyl coenzyme A (Acetyl-CoA) and oxaloacetic acid to citric acid  
 and CoA-SH ....................................................................................................................... 32 
Figure 7. Reaction of 5, 5’-dithiobis-(2-nitrobenzoic acid) (DTNB) and CoA-SH to 
 5-Thio-2-nitrobenzoic acid (TNB) and CoA-S-S-TNB........................................................ 33 
Figure 8. qPCR measurement for determination of the mtDNA copy number.................................. 36 
Figure 9. Illustration of the qPCR reaction in a linear regression curve............................................ 38 
Figure 10.  mtDNA copy number of HeLa wildtype and HeLa ρ0 cells................................................. 39  
Figure 11. Comparison of the absolute mtDNA copy number in different tissues of control  
 patients............................................................................................................................... 41 
Figure 12. POLG genotyping of a family with members affected by a mild phenotype  
 of PEO with epilepsy/ataxia ............................................................................................... 44 
Figure 13. Comparison of the mtDNA copy number in blood specimen of controls and a  
 family with members affected by a mild phenotype of PEO with epilepsy/ataxia  
 (daughter one and three) ................................................................................................... 45 
Figure 14. Depletion in blood samples of patients with Alpers-Huttenlocher syndrome..................... 49 
Figure 15.  COX-SDH double staining of liver slices............................................................................ 50 
Figure 16. Mitochondrial dysfunction in COX+ and COX- regions of postmortem liver of  
 patient one (p1) featuring Alpers-Huttenlocher syndrome................................................. 51 
Figure 17. mtDNA copy number in hippocampal subfields of patients affected by  
 temporal lobe epilepsy (TLE) ............................................................................................. 53 
Figure 18. mtDNA depletion in ddC- and EtBr-treated fibroblasts ...................................................... 55 
Figure 19. Detection of CS activity in ddC- (A) and EtBr-treated (B) fibroblasts ................................ 56 
Figure 20. Complex I-dependent respiration of fibroblasts.................................................................. 57 
Figure 21. Complex II-dependent respiration of fibroblasts................................................................. 58 
Figure 22. Complex I-dependent respiratory activity in ddC-treated fibroblasts ................................. 61 
Figure 23. Complex I-dependent respiratory activity in EtBr-treated fibroblasts ................................. 62 
Figure 24. Complex II-dependent respiratory activity in ddC-treated fibroblasts ................................ 65 
Figure 25. Complex II-dependent respiratory activity in EtBr-treated fibroblasts ................................ 66 
Figure 26. Correlation of mtDNA copy number and respiratory activity for ddC-treated  
 fibroblasts ........................................................................................................................... 68 
Figure 27. Correlation of mtDNA copy number and respiratory activity for EtBr-treated  
 fibroblasts ........................................................................................................................... 69 
Appendices 109
8.4 List of tables 
 
Table 1. Synthetic oligodeoxynucleotides for nuclear DNA as well as mitochondrial DNA  
 (mtDNA) ............................................................................................................................... 19 
Table 2.  Enzymes..............................................................................................................................  20 
Table 3.  Chemicals............................................................................................................................. 20 
Table 4.  Solutions............................................................................................................................... 22 
Table 5.  Kits ....................................................................................................................................... 22 
Table 6.  Measurement equipment ..................................................................................................... 23 
Table 7.  Other equipment................................................................................................................... 23 
Table 8.  Measurement software......................................................................................................... 24 
Table 9.  Other software...................................................................................................................... 24 
Table 10. qPCR reaction mix ............................................................................................................... 29 
Table 11. qPCR amplification protocol................................................................................................. 29 
Table 12. CS reaction mix.................................................................................................................... 33 
Table 13. Hits from NCBI BLAST search for pseudogenes of gene-sequences 
  from primer-amplified regions .............................................................................................. 37 
Table 14. Primer-dependent efficiency of qPCR reactions.................................................................. 37 
Table 15. Comparison of the influence of different DNA isolation methods on the mtDNA 
 copy number using cultivated wildtype fibroblasts ............................................................... 38 
Table 16. Content of mtDNA copies in human tissue samples............................................................ 40 
Table 17. Correlation between mtDNA content and CS activity .......................................................... 43 
Table 18. Nuclear and mitochondrial features of patients with a mild phenotype of PEO with 
 epilepsy/ataxia...................................................................................................................... 45 
Table 19. Genetic background and phenotype of patients with Alpers-Huttenlocher.......................... 47 
Table 20. Depletion in various tissues of patients with Alpers-Huttenlocher syndrome ...................... 49 
Table 21. mtDNA copy number distribution in liver regions of patient one (p1) .................................. 51 
Table 22. mtDNA copy number in hippocampal subfields of patients afflicted by temporal  
 lobe epilepsy (TLE) .............................................................................................................. 52 
Table 23. Measurement of the respiratory activity depending on complex I of ddC-treated 
 fibroblasts ............................................................................................................................. 60 
Table 24. Measurement of the respiratory activity depending on complex I of EtBr-treated  
 fibroblasts ............................................................................................................................. 60 
Table 25. Measurement of the respiratory activity depending on complex II of ddC-treated  
 fibroblasts ............................................................................................................................. 64 
Table 26. Measurement of the respiratory activity depending on complex II of EtBr-treated  
 fibroblasts ............................................................................................................................. 64 
Table 27. Standard amino acid abbreviations.................................................................................... 107 
 
 
List of publications 110
List of publications 
 
1. Baron M., Kudin A. P., and Kunz W. S. (2007) Mitochondrial dysfunction in 
neurodegenerative disorders. Biochem. Soc. Trans. 35, 1228-1231. 
 
2. Boes M., Bauer J., Urbach H., Elger C. E., Frank S., Baron M., Zsurka G., Kunz W. S., and 
Kornblum C. (2009) Proof of progression over time: finally fulminant brain, muscle, and liver 
affection in Alpers syndrome associated with the A467T POLG1 mutation. Seizure. 18, 232-
234. 
 
3. Paus S., Zsurka G., Baron M., Deschauer M., Bamberg C., Klockgether T., Kunz W. S., and 
Kornblum C. (2008) Apraxia of lid opening mimicking ptosis in compound heterozygosity for 
A467T and W748S POLG1 mutations. Mov Disord. 23, 1286-1288. 
 
4. Phillips J. R. , Fischer E. , Baron M., van den Dries N., Facchinelli F., Kutzer M., 
Rahmanzadeh R., Remus D., and Bartels D. (2008) Lindernia brevidens: a novel desiccation-
tolerant vascular plant, endemic to ancient tropical rainforests. Plant J. 54, 938-948. 
 
5. Zsurka G., Baron M. , Stewart J. D., Kornblum C., Bös M., Sassen R., Taylor R. W., Elger 
C. E., Chinnery P. F., and Kunz W. S. (2008) Clonally expanded mitochondrial DNA 
mutations in epileptic individuals with mutated DNA polymerase γ. J. Neuropathol. Exp. 
Neurol. 67, 857-866. 
 
 
These authors contributed equally. 
